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Abstract
Epilepsy is the most prevalent chronic brain disease affecting approximately 1% of the worldwide
population. Systemic treatment with anti-epileptic drugs are reported to only control seizures in up to
70% of the patients, while the remaining patients report insufficient seizure alleviation. Due to drug
resistance, an increasing concentration of the drug is required for systemic administration, resulting in
pronounced side effects. Localized drug delivery in the form of an implant enabling sustained drugrelease is regarded as a promising strategy to challenge refractory epilepsy.
Collagen, a naturally derived polymer, is one of the most useful biomaterials which has been widely
used in medical applications. Recently, an electrochemical technique has been developed to generate
oriented and highly clustered collagen fibres with increased mechanical stiffness. The objective of this
study was to investigate the potential to incorporate drug-loaded microspheres into electrochemical
compacted collagen (ECC) with a view to achieve a sustained dual drug-release profile. Dexamethasone
(DEX), commonly used to prevent acute inflammatory reactions after implantation, and phenytoin
(PHT), an anti-epileptic drug, were encapsulated into poly (lactic-co-glycolic) acid microspheres via
emulsification solvent evaporation technique. Sphere-loaded ECC membranes were successfully
prepared by suspension of the microspheres into the collagen solution prior to the electrochemical
compaction process. Tensile tests revealed that the incorporation of microspheres decreases the
tensile strength of ECC membranes by 25% from 1.11 ± 0.36 MPa to 0.73 ± 0.24 MPa. Finally, the drugrelease behaviour of sphere-loaded ECC membranes were investigated in an in-vitro experiment. Invitro release studies of DEX-MP/PHT-MP loaded ECC matrices showed DEX-elution to reduce from 86%
to 60% of completion at day 11, whereas PHT-elution was characterized by a high burst release
resulting in PHT-elution increased from 4% to 82% of completion at day 1.
In conclusion, the incorporation of drug-loaded microspheres into ECC membranes demonstrates a
promising approach for the development of novel collagen-based drug delivery systems with increased
mechanical properties. The data indicates that sustained drug release from ECC matrices highly
depends on the ability of the targeted drug to undergo the electrochemical fabrication process and
thus further studies need to be performed in order to receive an in-depth understanding of the
procedure.
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1. Introduction
The focus of this work is the fabrication of durable collagen films for a neurosurgery application with
the capacity and capability of dual drug release. Anti-inflammatory dexamethasone (DEX) and antiepileptic levetiracteam (LEV) or phenytoin (PHT) are the drugs considered for this study. The objective
of this chapter was to give the reader a clear picture of the surgical application of collagen devices, the
need for novel treatment strategies for refractory epilepsy, specifically regarding the fabrication
aspects.

1.1 Collagen
1.1.1 Biological background
Collagen typifies the primary structural protein representing about 30% of the body proteins in
humans [1]. To fulfil various biological features collagen can present itself in 13 different
configurations [2]. All subtypes of collagen represent a particular triple-helix arrangement of three
polypeptide subunits, also known as α-chains. Type I collagen is the basic configuration of collagen
responsible for the mechanical integrity of tendons and ligaments. It consists of two α1 and one α2
chains, in which a high quantity of glycine is present. Due to its small side group and its frequent
appearance within the α-chain, the polypeptide chains are able to form a close arrangement into a
helix [3]. To fulfil its characteristic physiological and biological properties, the triple-helical collagen
molecules are assembled longitudinally and bilaterally into fibrils. Larger constructs of collagen are
formed through the organization of fibrils into greater fibre bundles (Fig. 1) [4].

Figure 1. Assembly of collagen molecules to fibres. Formation of the triple-helical structure consisting of three polypeptides
subunits, followed by the removal of the terminal peptides of procollagen by procollagen peptidase. Helices are assembled
to collagen fibrils after secretion from the cell followed by the assembly of fibrils to collagen bundles [5].
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Along with the physiological assembly of fibrils, cross-linking of the collagen structure is essential for
the mechanical and chemical stabilization of collagen fibrils. Intra- and intermolecular crosslinking of
fibres is catalyzed by lysyl-oxidase during fibril formation. Lysyl-oxidase generates highly reactive
aldehyds from lysin sidechains of the triple-helix. These activated side chains can easily undergo
spontaneous chemical reactions like Schiffs’ base type or aldol condensation type crosslinking [6].

1.1.2 Collagen matrices for dural repair in neurosurgery
Collagen is regarded as one of the most beneficial biomaterials which has been adopted in several
medical applications. The advantage of collagen-derived products is mostly based on its excellent
biological compatibility and safety due to biodegradability and weak antigenicity properties [7]. Due
to its superior properties, the use of collagen in biomedical application has been rapidly expanded,
including its use in drug delivery systems, tissue-engineering and surgical devices. One of the most
promising applications of collagen, regarding its use in surgeries, is to support the post-operative dura
mater regeneration (Fig. 2) [8].

Figure 2. Collagen-based resorbable membrane CovaTM for post-operative adhesion [9].

The dura mater is a thick membrane and the outermost of three layers surrounding the brain and the
spinal cord. Because it almost completely surrounds the brain tissue, neurosurgeons often must
perforate this dural layer to perform a procedure. This process can lead to dural defects including
retraction, shrinkage or excision [8]. To minimize the development of such defects, dural grafts, made
of either metallic or synthetic material are used to prevent post-operative adhesions. These layers of
scar tissue often occur after surgical invasive operations [10]. Excess of scar tissue is a severe condition
- 11 -

for patients who depend on multiple surgeries as it is difficult to penetrate during medical
interventions [11].
In contrast to the low biological performance of metal or synthetic polymeric grafts, collagen fleeces
promote the vascularization and the reconstitution with host cells, while minimizing the immunological
body response [12]. Tacho-Comb, a commercialized fibrinogen-based collagen fleece mostly used in
vascular surgery, was firstly evaluated by M. Reddy et al. to demonstrate its superior suitability as a
dural substitute in neurosurgery application [8].

1.1.3 Electrochemical compaction of collagen
For the application of collagen in surgeries, a significant challenge is the ability to provide suitable
mechanical properties to ensure safety and facilitate handling of the devices. In the native tissue, the
density and high orientation of collagen provides the mechanical and structural strength of loadbearing extracellular matrices [13]. An assembly process of collagen which enables the fabrication of
dense, oriented, tissue-like constructs would thus highly increase the application range of collagen. In
the last decades a variety of techniques including dehydration processes, electrospinning or
anisotropic chemical nanopatterns, were developed to synthesize collagen structures with increasing
degree of orientation [14-16]. However, all these techniques have different limitations regarding costeffectiveness, toxicity of solvents or time frame. Recently an electrochemical alignment procedure,
referred to as electrochemical compaction, was developed by X. Cheng et al. to generate
extraordinarily oriented and highly compressed collagen bundles from aqueous monomeric collagen
solution (Fig. 3) [17].

Figure 3. Electrochemical compaction of collagen molecules during the electrolysis of water. Monomeric collagen between
the electrodes assumes different net charges due to its amphoteric nature. Repulsion from the same charged electrodes
causes compaction of the collagen chains at the isoelectric point [18].
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In general, the electrochemical reaction used in this process is based on the electrolysis of water. At
the anode, oxygen and oxonium ions are formed due to the reduction of water leading to an acidic
environment. In contrast, oxidation of water to hydroxide ion and hydrogen at the cathode forms a
basic milieu [17]. The induced pH gradient causes different net charges of the collagen molecules. Next
to the anode collagen gets a positive charge and those molecules close to the cathode assume a
negative charge. The similar charge of collagen as compared to the electrodes triggers repulsion of the
molecules towards the isoelectric point of collagen, where the total charge is zero and a compaction
of molecules occurs [19]. Studies on the cell migration through 3D bundles of collagen fabricated using
this process have shown that these collagen structures are conductive to cell proliferation [17]. Apart
from collagen bundles, further investigation into this electrochemical fabrication process could provide
a solution to collagen device fabrication, representing differences in architectural complexity and
composition [20-22]. This technique could also be a promising method to prepare collagen membranes
with increased mechanical strength, making it suitable for applications such as an adhesion barrier in
neurosurgery.

1.2 Epilepsy
Epilepsy is the most prevalent chronic brain disease affecting approximately 1% of the worldwide
population, it is associated with significant morbidity and mortality rates [23-25]. Even if it is regarded
more than a diverse group of dysfunctions underlying abnormal electrical transmission of brain
neurons, all forms of epilepsy reveal the hallmark characteristic of periodic irrepressible seizures [26].
Epilepsy is versatile, demonstrating around 15 specifiable types of seizures and about 30 epilepsy
syndromes [27, 28]. In general, these seizures are classified into focal seizures, in which the epilepsy
focus appears at a cortical site, and generalized seizures, in which the neuronal disorder is distributed
in both hemispheres of the cortex. The impact of seizure to the patients’ wellbeing can be motor, like
brief shock-like jerks of muscles (myoclonic), sudden stiffness of bodyparts (tonic) or loss of muscle
tone (atonic). Tonic-clonic seizures, the most common type associated with epilepsy patients, appear
as a loss of consciousness and muscle stiffness which is followed by rhythmical jerking of the
extremities. Aside from these physiological symptoms, there are also known non-motor symptoms like
lapses in awareness which is present in absence seizures. The classification of epilepsy seizures is still
a field of research and undergoes dynamic change [29]. Despite research efforts over the last decades,
the exact mechanism causing neurochemical irregularities present in epilepsy are still not completely
understood [30]. In the normal brain, signal transmission is organised non-synchronously and is
regulated by a highly clocked mechanism (Box 1). In Epilepsy patients this regulation breaks down due
to either, the reduction of inhibitory neurotransmission or through an increase in excitatory
- 13 -

transmission resulting in a state of uncontrolled hypersynchronous and excitatory firing of brain
neurons [31]. The instance by which the intact brain is degenerating towards this electrical abnormality
is termed epileptogenesis. As Goldberg et al. declares this process is basically classified in three stages:
the incident of a procuring event, continued by an inactive period of time during which changes happen
in motion and third, chronic established epilepsy. Factors which can trigger epileptogenesis vary
greatly and can include; acquired brain pathology, like tumours, infections and injuries as well as
mutations in single genes or neurodevelopmental disorders which can influence the formation of an
epileptic brain [24].
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Box 1: Neuronal communication pathway in the normal brain
Neurons are the key structure in the nervous system responsible for receiving and sending signals. Due
to the expression of ligand- and voltage-gated membrane-channels neurons are capable to create
potential variations between the inside of the cell and the outside membrane [32]. The resting
membrane potential relays mostly to the difference between positively charged ions inside and outside
the cell at rest and is approximately -70 mV [33]. Binding of neurotransmitters at the membrane
receptor causes opening of ion channels which enables positive ions to enter the neuron. This process
causes a change of potential and leads to firing of so-called action potentials. Creation of an action
potential is an “all-or nothing” event what means that the neuron starts to depolarize completely when
threshold potential is reached (Fig. 4) [34].

Figure 4. Electrical transmission in brain neurons. Depolarization of the neuron occurs due to opening of sodium channels
during the span of a spike. Following a spike, repolarization occurs due to closing of the sodium channels which leads to
hyperpolarization of the neuron. The resting potential of the neuron is restored by ion pumps [35].

Repolarization of the cell begins due to closing of Na+ channels to reset the resting potential of the cell.
In this period the cell is unable to form further action potentials. While closing the sodium gateway
potassium ions rapidly leaving the cell through voltage-gated K+-channels and causes a strong
negatively potential called hyperpolarization. Once the hyperpolarized potential is achieved sodium
channels will be opened again for adjusting the cells’ resting potential [34-36].
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1.3 Pharmacologic mechanism of anti-epileptic drug action
Therapies with anti-epileptic drugs (AEDs) still remain the mainstay in epilepsy treatment, even though
the prescription of these drugs is only used to symptomatically supress seizure once they occur [37,
38]. So far, there is no AED known that has been demonstrated to inhibit the occurrence of epilepsy in
patients prior to the first seizure event [39]. Application of AEDs aims to reduce the passing of electrical
or chemicals signals in the neuronal network to return electrical transmission to a normal level.
Transmission of stimuli in the brain takes place at synapses, the structure of neurons in which the
action potential of the excitatory cell is propagating. Even if in the last decades a broad spectrum of
new AEDs has been developed, their mechanisms of action is still classified into three basic mechanism
on the cellular level: adjustment of voltage-dependent ion channels (Na+, Ca2+, K+), augmentation of yaminobutyric acid (GABA)-related inhibitory activity and reduction of excitatory (glutamate-related)
transmission (Fig. 5) [31, 40].

Figure 5. Action sites of common AEDs. Reduction of the electrical signal transmission due to either suppression of voltagedependent ion channels, up-regulation of GABA-mediated inhibitory neurotransmission or reduction of Glutamate-mediated
excitatory neurotransmission [41]..

A large range of drugs act by modulation of voltage-gated ion channels (VGCs) through binding at
specific subunits at the membrane receptors [42, 43]. Through blocking of subunits, for example the
Na+ channel by AEDs, sodium can’t enter the neuron and depolarize the cell which is necessary for the
neurotransmitter release. Due to this action common AEDs like phenytoin (PHT) and carbamazepine
hinder rapid bursts of action potentials in an effective manner [44]. Potassium-channels are another
well-known target for anti-convulsant drug action. On the cellular level K+ channels are responsible for
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the repolarization of the plasma membrane after sodium influxes [45]. Thus, activation of these
channels would immediately hyperpolarize the neuronal cell and limits action potential firing [46].
Retigabine is a novel AED that exerts its anti-convulsive effect by initialization of the KCNQ K+
channels [47]. The GABA system demonstrates one of the most favoured action target for the
development of novel AEDs [48]. GABA is a major inhibitory neurotransmitter in the mammalian
central nervous system (CNS) [49]. Through binding of specific GABA-receptors at the inhibitory
synapses Cl- conductance is increased which leads to neuronal hyperpolarization [50]. Increased GABA
release and synthesis [51], allosteric receptor facilitation [52], and minimized deactivation [53] are
targets which have all been applied in the pharmacologic mechanism of clinically used AEDs [54]. The
antagonist of GABA is the excitatory glutamate. Glutamate represents the most important excitatory
neurotransmitter in the human nervous system and is stored in the so called vesicles at chemical
synapses [55]. Following synaptic release, it can bind at ionotropic glutamate receptors. These
receptors are principally classified into AMPA, Kainate and NMDA subtypes, forming ligand-gated ion
channels for sodium or calcium influxes [56]. Even though none of the AEDs provides its anti-convulsive
activity solely by interacting with the glutamate system, blockade of glutamate receptors is regarded
to assist in the anti-epileptic action of many drugs like, perampanel [56-58].

1.4 Drug delivery for epilepsy
The development of pharmacological active components alone is not sufficient for the successful
therapy of CNS-diseases, like Alzheimer, Parkinson or epilepsy. The development of adequate drug
delivery strategies that are able to tackle the biological barriers and release the drug to a targeted area
is a major challenge in pharmacology [28, 59].

1.4.1 Limitation of oral dosage forms
For the therapy of epilepsy, the common approach is to use AEDs via oral route. However, this method
only achieves a satisfactory result in 70% of the patients while the remaining patients are unable to
achieve sufficient seizure alleviation [60, 61]. The phenomenon of unresponsiveness to oral applied
AEDs seems to be multifactorial, but there is evidence that suggest that the blood-brain barrier (BBB)
plays an important role [62]. The BBB segregates blood and brain interstitial fluid and protects the
brain from harmful compounds. This unique biological function is provided by brain vascular
endothelial cells which form highly resistant tight junctions. Crossing this cerebral microvasculature
barrier is only possible for lipid-mediated or carrier/receptor-mediated transporters [63]. Additionally,
another key structure of the BBB are molecular efflux pumps, which can effectively restrict the
penetration of commonly AEDs into the brain by pumping them into the vessel lumen [64].
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Overexpression of some multidrug resistance proteins has been proved in patients with refractory
epilepsy [65]. Due to the drug resistance, an increasing concentration of the AED accumulates in the
circulation instead of the brain as the desired target. A high level of AEDs in the circulation leads to
intolerable systemic side effects which massively decrease the patients’ wellbeing [66]. Furthermore,
oral consumption of AEDs is an unspecific way for penetrating the seizure focus. As a result of the
delivery through the BBB the anti-epileptic active compounds interfere with the function of all
neuronal cells in the CNS which can provoke cerebral side effects (e.g. ataxia, sedation and mood
change) [67].

1.4.2 Local drug delivery
As mentioned before, the BBB is the chief factor restricting the anti-convulsive effect of oral dosage
forms, which resulted in the development of new strategies to enhance the concentration of AEDs in
the brain, including drug delivery systems [68], prodrugs [69], inhibition of molecular efflux pumps
[70], disruption of the BBB [71], direct injection behind the BBB [72] as well as gene and cell therapies
[28]. Under all these strategies the most promising approach emerged in the field of localized drug
delivery. As mentioned before, a delivery system that could release its pharmacological payload
specifically to the epileptic focus would be unfavorable for two reasons. First, a high concentration of
the drug would be realized and second, it minimizes the toxic effect on the intact neuronal network.
Application of the drug into the cerebrospinal fluid (CSF) can be an alternative to common treatment
of epilepsy because of the direct delivery of the drug bypassing the BBB [73, 74]. The main advantage
of this method is the decreased systemic toxicity. However, intracerebroventricular injection of AEDs
has some limits regarding the transport to the epileptic seizure area. As drug movement is controlled
by diffusion the brain penetration of AEDs is limited to ependymal cells which line the ventricles (Fig. 6)
[75]. Furthermore, a fast exit of the drug from the brain is caused by flushing into the circulation [76].

Figure 6. Low penetration of neurotrophic factors (radiolabeled) into the brain parenchyma at 20 h after
intracerebroventricular injection [68].
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To overcome many of the drawbacks of the intracerebroventricular administration direct transport of
anti-convulsant drugs into the brain parenchyma seems like a suitable alternative. Clinically useful local
drug delivery systems for epilepsy have been developed over the past decade. One of the most
promising methods is the construction of polymer-based implants that serve as a drug reservoir for
long term release of AEDs [77]. In general, polymeric devices are classified as biodegradable and nonbiodegradable polymers. In the case of biodegradable polymers, the body’s own degradation
processes, e.g. hydrolysis or enzymatic degradation, breaks down the medical device, leading to a slow
gradual drug release near the target area over time. An advantage of biodegradable implantable
devices is the elimination of surgeries required to replace the implant, compared with nonbiodegradable devices. However, for an effective clinical use these implants have to fulfil a range of
important properties. First of all, the degradation time of the biomaterial must be aligned with the
regeneration time for the surgical intervention. In addition, the body's inflammatory response incurred
by implantation must be prevented [67]. Furthermore, the medical device should have mechanical
properties similar to the target area of the body without compromising permeability and processability
[78].
Initial studies of polymer-based implants performed by M. Kokaia et al. have shown a sustained release
of anti-convulsant drug. In an animal model, the implantation of a GABA-eluting polymeric device into
the hippocampus of a rat, showed the ability to ameliorate seizure strength for up to 2 days [72]. In
the past few years research has focussed on improving the long-time drug-release properties of
polymer-based implants. To achieve a sustained long-term drug release, several studies have
investigated the combination of microparticles (MP) and monolithic devices to provide slow release of
the drug [79-81]. As an example of such a device, Szybala et al. demonstrated drug release for 21 days
from an implant containing drug-loaded silk microspheres embedded in multiple layers of silk.
Investigations into the potential of such a device to prevent seizures were carried out in a rodent model
of temporal lobe epilepsy, which demonstrated 10 days of seizure suppression after implantation.
Despite progress over the last few decades to extend the drug-release properties of implantable
devices, an appropriate implant for refractory epilepsy treatment has still not been achieved. Due to
the high risk of intracranial infection or neurological deficits related to neurosurgical implantation of
the device, Hallidays et al. mentioned, that the main challenge for an clinical application of the implant
is to create a device, which is able to provide seizure alleviation for at least 12 months [67].
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1.4.3 Encapsulation of drugs
Over the last few decades several methods have been progressed to encapsulate core materials into
polymeric microspheres. In general, these techniques are grouped into chemical procedures (e. g. In
situ polymerization, polycondensation), physio-chemical procedures (e. g. Sol – gel encapsulation,
coacervation and phase separation) and physico-mechanical procedures (e. g. Spray drying and
congealing, solvent evaporation) [82, 83]. Among these techniques, emulsification solvent evaporation
(ESE) is a well-defined technique commonly used for encapsulation of pharmaceutical compounds. The
ESE process is divided in two steps (Fig. 7).

Figure 7. Double-emulsion technique for hydrophilic MP. An aqueous drug-loaded phase (W) is emulsified into a polymer
containing oil phase (O). The primary emulsion W/O is further emulsified into an outer aqueous phase(W) to fabricate drugloaded oil droplets. Evaporation of the volatile organic solvent causes solidification of the microspheres [84].

For hydrophobic drugs, like DEX, the first step includes emulsification of the polymer- and drug-loaded
oil phase into an aqueous phase. Due to the high shear stress produced during the emulsification, the
polymer-containing oil phase is highly dispersed in microdroplets. The MP size is the main parameter
influenced by this primary step [85]. Encapsulation of a hydrophilic drug, like LEV, requires two
emulsification steps. An aqueous phase of the compound is mixed into a polymer containing oil phase,
forming a primary emulsion (W/O). Addition to a second water phase results in the formation of oil
droplets including a drug-loaded aqueous phase (W/O/W) [86]. In the second step, the solvent is
removed by evaporation of the volatile compounds and the final polymer precipitation takes place,
leading to the formation of microspheres. The parameters determined by the second step of the ESE
are the morphology of generated MPs which have crucial influence on the encapsulation efficiency
and release behaviour (Fig. 8) [87].
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Figure 8. Influence of the precipitation on MP morphology. Fabrication of porous microspheres due to the delayed polymer
precipitation results in low encapsulation efficiency. Fast polymer precipitation provides high encapsulation efficiency due to
the formation of a uniform shell of the microsphere [88].

In principle high encapsulation efficiency of drugs are obtained by a fast solidification of MPs which is
influenced by several parameters [89]. As Mehta et al. mentioned, a low solubility of the polymer in
the oil phase decreases solidification time of the microspheres [90]. In addition, high solubility of the
organic liquid in water benefits the encapsulation procedure leading to rapid precipitation of the
polymer, based on a fast mass-transfer between the dispersed (DP) and the continuous phase
(CP) [89]. Increasing the polymer concentration is another crucial parameter resulting in high
encapsulation efficiency. This relationship can be interpreted in two ways, on the one hand that the
polymer has a faster precipitation on the surface of the DP, and on the other hand it prevents drug
diffusion across the phase boundary [91, 92]. Additionally, a high concentration of polymers results in
an increase in viscosity and thus causes a delay in drug diffusion. The ratio between the DP and the CP
also has an important influence on the solidification of microdroplets. A large volume of the CP leads
to a high concentration gradient resulting in an enhanced solidification rate of the MPs [90, 92].
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1.5 Aims and objectives
As can be seen from the preceding literature investigation the need for novel treatment strategies for
refractory epilepsy is indubitable and several different materials and fabrication methods are available
to achieve this aim. Nevertheless, there are also some boundary conditions mostly related to the
regulatory guidelines to guarantee patients safety.
The ultimate goal of this thesis is the development of a novel implantable medical device hallmarked
by sustained dual-release of an anti-convulsive drug for the treatment of pharmaco-resistant epilepsy
and an anti-inflammatory agent to support post-operative wound-healing. To realize this aim, the
project investigates the possibility of incorporating microspheres, loaded with anti-inflammatory DEX
and AEDs (LEV or PHT), into the electrochemical compaction process of collagen to form a unique
collagen-based drug delivery system (Fig. 9). To achieve encapsulation of hydrophobic DEX, the single
ESE technique (O/W) is investigated and for the hydrophilic LEV the double ESE technique (W/O/W) is
used.

Figure 9. Concept of the fabrication process of drug-loaded collagen sheets. Drug-loaded microspheres are mixed to the
monomeric collagen solution and injected between the electrodes. Application of an electrical field triggers the compaction
of collagen molecules at the isoelectric point and causes entrapment of the microspheres within the collagen sheet.

The success of the concept for a clinical application, as illustrated above, is dependent on three factors:
I, drug-loaded collagen matrices have to meet the criteria for an application in neurosurgery regarding
a sufficient mechanical stiffness of the device.
II, the target fabrication process has to provide a sufficient drug-loading efficiency
III, the release kinetics of the implant must be in consistent with the therapeutic window of inserted
drug to guarantee patients safety.
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2. Materials and Methods
2.1 Microsphere preparation
2.1.1 Encapsulation of DEX
For the encapsulation of hydrophobic DEX, the single ESE technique (O/W) was used. Poly (lactic-coglycolic) acid (PLGA) with a lactide:glycolide ratio of 50:50 (Purasorb® PDLG 5010, Mw =153 kDa) was
utilized for all microsphere formulations. In general, PLGA was dissolved in 6 mL dichloromethane
(DCM). The concentration of PLGA varied from 5% w/v, 10% w/v, 15% w/v and 20% w/v. Each oil phase
was then emulsified into 60 mL of 2% w/v poly-vinyl alcohol (PVA) aqueous solution at 8000 rpm for 3
min using an IKA® T25 digital ULTRA-TURRAX® homogenizer. The emulsion was then added to 60 mL
of deionized water and stirred at 800 rpm at room temperature. After 3 h, the microspheres were
isolated by centrifugation at 3000 rpm for 4 min, washed 3 times with distilled water to get rid of any
residual PVA and lyophilized for 2 days. MPs were stored under dry conditions at -20 °C and protected
from light.

2.1.2 Encapsulation of rhodamine B isothiocyanate-dextran
PLGA microspheres were prepared by a W/O/W emulsion technique previously reported by Freytag et
al.. 0.5 mg of rhodamine B isothiocyanate-dextran was dissolved into 500 µL of distilled water (forming
internal aqueous phase, W). Afterwards the aqueous solution was added to 5 mL of DCM containing
1 g PLGA (O). The primary emulsion was vortexed at 2500 pm for 30 s followed by 5 min of sonification.
The W/O emlusion was then added to 10 mL of 4% PVA solution (re-emulsification solution, W) and
vortexed at 2500 pm for 30 s. The resulting W/O/W double emulsion was poured into 250 mL of 0.4%
PVA solution and stirred at 1000 rpm. After 2 h, the MPs were isolated by centrifugation at 3000 rpm
for 4 min, washed 5 times with distilled water to get rid of any residual PVA and lyophilized for 2 days.
MPs were stored under dry conditions at -20 ⁰C and protected from light.

2.1.3 Encapsulation of LEV
For the encapsulation of hydrophilic LEV various batches of microsphere formulations were developed
using various methods like water-in-oil-in-oil (W/O/O) double emulsion solvent diffusion (ESD) and
W/O/W double ESE techniques. PLGA with a lactide:glycolide ration of 50:50 (Purasorb® PDLG 5010)
and 75:25 (Purasorb® PDLG 7507, Mw = 95 kDa) were used as the controlled release polymers.
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W/O/W Double ESE method using DCM
Briefly, 100 mg of LEV was dissolved into 500 µL of distilled water (forming internal aqueous phase).
Next, the aqueous solution was added to 5 mL of DCM containing 1 g PLGA (oil phase). The primary
emulsion was vortexed at 2500 rpm for 30 s followed by 5 min of sonification. The mixture was then
added to 10 mL of 4% PVA solution (re-emulsification solution) and vortexed at 2500 rpm for 30 s. The
resulting W/O/W double emulsion was poured into 250 mL of 0.4% PVA solution and stirred at
1000 rpm. After 2 h, the MPs were obtained by centrifugation at 3000 rpm for 4 min, washed 5 times
with distilled water to remove any residual PVA and lyophilized for 2 days. MPs were stored under dry
conditions at -20 °C and protected from light.

W/O/W Double ESE method using ethyl acetate
PLGA microspheres were prepared by a modified W/O/W ESE technique previously reported by F.
Meng et al. [86]. 40 mg of LEV was dissolved into 200 µL of distilled water and then added to 2 mL of
ethyl acetate (EA) containing 200 mg of PLGA with a lactide:glycolide ratio of 75:25. The primary
emulsion was vortexed at 2500 rpm for 30 s and re-emulsified at 2500 rpm for 60 s with the external
aqueous phase containing 2% PVA. Next, the W/O/W double emulsion was poured into 20 mL of
another aqueous phase containing 2% PVA and stirred at 100 rpm for 2 min to pre-solidify the
microdroplets. Subsequently, the W/OW emulsion was poured into 200 mL 1% PVA solution and
stirred at 400 rpm to solidify the embryonic microdroplets. After 4 min, the microspheres were
obtained by centrifugation at 3000 rpm for 4 min, washed 3 times with distilled water to get rid of any
residual PVA and lyophilized for 2 days. MPs were stored under dry conditions at -20 °C and protected
from light.

W/O/O Double ESD using paraffin oil
PLGA microspheres were prepared by a W/O/O ESD technique previously described by Wu et al. with
some modifications [93]. Briefly, 200 mg of PLGA (50:50) was dissolved in 2 mL of a mixed solvent
system comprising of acetonitrile (ACN) and DCM in equal volumes (1:1). 20 mg of LEV was dissolved
in 200 µL of distilled water. The aqueous phase was mixed in the above organic phase and vortexed at
2500 rpm for 60 s to form the W/O emulsion. Afterwards, the W/O emulsion was emulsified into 50 mL
of liquid paraffin containing 0.5% Span80. The W/O/O emulsion was stirred at 750 rpm for 4 h at room
temperature to evaporate the organic solvents. The MPs were obtained by centrifugation at 3000 rpm
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for 4 min, washed 3 times with 20 mL of n-hexane to remove any residual surfactant and lyophilized
for 2 days. MPs were stored under dry conditions at -20 °C and protected from light.

2.1.4 Encapsulation of PHT
PHT-loaded microspheres were prepared by a modified O/W ESE procedure [94]. PLGA with a
lactide:glycolide ratio of 50:50 (Purasorb® PDLG 5010) was utilized for all microsphere formulations.
PLGA and PHT were dissolved in 5 mL of DCM and acetone (4:1) at a weight ratio of 10:1. The
concentration of the polymer varied from 10% w/v, 15% w/v and 20% w/v. The organic phase was then
emulsified into 50 mL of 2% PVA aqueous solution at 8000 rpm for 3 min using an IKA® T25 digital
ULTRA-TURRAX® homogenizer. Afterwards, 50 mL of distilled water was added to the O/W emulsion
and stirred at 1000 rpm at room temperature for 4 h. The MPs were obtained by centrifugation at 3000
rpm for 4 min, washed 3 times with 0.2% w/v PVA solution to remove any residual surfactant and
lyophilized for 2 days. MPs were stored under dry conditions at -20 °C and protected from light.

2.2 Characterization of microspheres
The volume-mean diameter of the drug-loaded microspheres was quantified using photomicrographs
taken on a Zeiss Axiovert 40 CFC microscope. Images of PLGA microspheres were analyzed using NIH
ImageJ software. At least 400 particles were evaluated to generate the distribution of particle
diameter.

2.3 Loading efficiency
The amount of drug per weight of microspheres was determined by a solvent extraction method.
Briefly, 5 mg of MPs was weighed and extracted with ethanol overnight. Samples were then
centrifuged at 1000 rpm for 5 min and the supernatant was collected. The amount of the drug was
quantified by HPLC analysis. An Agilent 1260 Infinity HPLC system was utilized, equipped with a
ZORBAX® Eclipse Plus C18 column (4.6 mm x 100 mm, 5 µm). The temperature of the column was
adjusted at 40 °C, the injection volume was 10 µL, the flow rate 1.0 mL/min, and UV detection
wavelength at 242 nm. The amounts of DEX and PHT were analyzed using an isocratic mobile phase
consisting of water and ACN (70:30, v/v). A standard curve of DEX and PHT prepared in 1 x PBS aqueous
solution was established by plotting the peak areas against respective concentrations of standard
solutions, respectively.
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2.4 In-vitro drug release study of microspheres
10 mg of drug-loaded microspheres were suspended in 1 mL of artificial cerebrospinal fluid (aCSF,
0.866 wt% NaCl, 0.224 wt% KCl, 0.0164 wt% MgCl·6H2O and 0.0206 CaCl2·6H2O in 0.001 M PBS), and
the release experiment was conducted at 37 °C in a shaker water bath. For each sample, the release
medium was obtained by centrifugation at 4000 rpm for 3 min and replenished with fresh aCSF at
various time points and stored at -18 °C prior to HPLC analysis being undertaken.

2.5 Fabrication of particle-loaded ECC matrices
Acid soluble type-I bovine collagen solution (Advanced BioMatrix, 6.1 mg/mL) was diluted 1-fold in 20
mM acetic acid and dialyzed (Mwcut off = 12-14 kDa) against ultrapure water for 18 h. 5 mg of drugloaded PLGA MPs were added to 1 mL of freshly dialyzed collagen (3 mg/mL) solution and vortexed at
2500 rpm for 30 s. This emulsion was injected between two plate electrodes and a voltage of 6 V was
applied for 20 minutes. At the end of the electrochemical process, the ECC matrices were recovered
from the cathode using a pair of tweezers. To promote fibril formation, the fabricated ECC matrices
were incubated in 10 times phosphate-buffered saline (PBS) containing 0.5 mM riboflavin at 37 °C for
2h. After incubation, collagen matrices were exposure to an UV light source (400 nm) for 120 seconds
to initiate crosslinking. Crosslinked ECC matrices were then washed thoroughly 3 times prior to the invitro drug release study.

2.6 Tensile mechanical properties
The influence of microsphere entrapment on the mechanical properties of ECC matrices was analyzed
by using a Shimadzu EZ mechanical tester. In-plane tensile tests were performed on ECC sheets (12.5
mm x 8 mm x 0.2 mm) with and without microspheres (N=3/group). Samples were fixed on paper tabs
and rehydrated with 1x PBS. The thickness of the ECC matrices were determined using an optical
microscope (Zeiss Axiovert 40 CFC). Afterwards, the samples were mounted onto the tensile clamps
with 10 mm gauge length and subjected to uniaxial tensile loading until failure at a strain rate of 1
mm/min. The load-displacement data were used to calculate the Young´s modulus of ECC matrices.

2.7 In-vitro drug release study of ECC matrices
Drug-loaded ECC matrices (N=3) were suspended in 1 mL of aCSF and the release experiment was
conducted at 37 °C in a shaker water bath. For each sample, the release medium was collected and
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replenished with fresh aCSF at various time points and stored at -18 °C prior to HPLC analysis being
undertaken.

2.8 Scanning Electron Microscopy (SEM)
To assess the microscopic morphology of the ECC matrices, SEM was undertaken on the compacted
collagen matrices and MP-loaded collagen matrices. An analogue sample preparation method was
utilized, as recently described by Kishore et al. [19]. First, collagen matrices were fixed in 3.7 %
paraformaldehyde for 3 h. Next, the samples were dehydrated in ethanol: water solutions (20%, 50%,
75%, 90% and 100% ethanol) for 5 minutes each. The matrices were then allowed to dry at room
temperature overnight followed by Pt sputter coating. The surface and cross-section of the prepared
collagen samples were observed under high resolution SEM (JEOL JSM-7500 field emission SEM).
Additionally, the morphology of the microspheres was analyzed using a field emission scanning
electron microscope (JEOL JSM-7500). The MPs were sputter-coated with Pt to avoid sample charging.
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3. Results and Discussion
3.1 Fabrication of drug-loaded microspheres
3.1.1 Characterization of DEX-loaded microspheres
DEX-loaded PLGA microspheres were successfully prepared by an O/W ESE technique (Fig. 10). To
investigate the optimized PLGA concentration regarding its encapsulation efficiency of the drug
samples were prepared using 5%, 10%, 15% and 20% PLGA.

Figure 10. Photomicrographs of the microspheres prepared using an O/W emulsion from (A) 5%, (B) 10%, (C) 15% and (D)
20% PLGA.

An increase of the PLGA concentration correlated with an increase of the particle size of the spheres
with a broader distribution (Table 1). Analysis of the drug-loading efficiency showed low encapsulation
of DEX for microsphere formulations with low PLGA concentrations. Due to an increase of the polymer
concentration up to 20% an acceptable drug-loading of 51% could be obtained.
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Table 1. Summary of microsphere characterization at different PLGA concentrations.

Concentration of
PLGA

Average particle size
(µm)

Drug loading efficiency (%)

5% PLGA

6.1 ± 1.1

11.9 ± 0.9

10% PLGA

15.5 ± 2.9

12.5 ± 0.8

15% PLGA

20.3 ± 8.5

13.4 ± 1.3

20% PLGA

21.9 ± 5.7

51.4 ± 4.9

As previously mentioned, this phenomenon is mostly related to the fast solidification of the
microspheres during the O/W emulsion which leads to an enhanced encapsulation efficiency of the
hydrophobic drug into the particles. Moreover, SEM-Imaging of 20% PLGA microspheres demonstrated
a spherical structure with smooth surface morphology (Fig. 11).

Figure 11. SEM micrographs of the DEX-loaded MPs prepared from 20% w/v PLGA using an O/W emulsion method taken at
x600 (A) and x2500 (B) magnification.

To characterize the DEX-release profile from the 20% PLGA microspheres, an in-vitro release study was
investigated in an aCSF (pH 7.4) solution at 37 °C for 11 days. The DEX-release profile from the PLGA
microsphere samples showed multi-stage eluting behavior (Fig. 12).
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Figure 12. Cumulative DEX released from the 20% PLGA microspheres during an in-vitro release study in aCSF (pH 7.4) at
37 °C (n = 3) for 11 days. (A) Quantitative release of DEX per mg microspheres. (B) Total amount of DEX released as a
percentage of the total amount of drug encapsulated into the 20% PLGA microspheres.

DEX-release from the PLGA microspheres followed a multi-stage pattern. An initial burst release of the
anti-inflammatory drug has been observed with approximately 20% of the payload released during the
first 6h. The phenomenon of this initial burst release can be explained by the release of DEX localized
on the surface of the microspheres. Furthermore, as a general observation, it is noteworthy that the
obtained PLGA microspheres, as for most particle formulations prepared by ESE, indicate a high
variability (Fig. 11). As described by Berchane et al., a high polydispersity in size correlates with a high
initial burst release, since a significant amount of drug is entrapped into smaller particles, which
demonstrate brief elution times [95].
The subsequent days (1 to 8) showed a decreasing release rate of DEX, associated with the slight
diffusion of the drug from the core of the microspheres into the medium. The third stage was
characterized by a steady state, reaching 86% of completion until conclusion of the in-vitro release
study after 11 days.
Summarizing the above, ESE provided drug-loaded microspheres which showed sustained release of
DEX for 11 days. As for the anti-inflammatory drug, a controlled release profile for the crucial initial 2
weeks of post-implantation was desired, the 20% PLGA microsphere formulation showed promising
results for the incorporation into ECC matrices.

3.1.2 Encapsulation of anti-epileptic LEV
As previously discussed, a great variety of methods, mostly based on single-emulsions, have been
utilized to fabricate drug-loaded microspheres but are mainly limited to hydrophobic drugs. To ensure
the encapsulation of hydrophilic drugs, which show rather low solubility in most organic solvent
- 30 -

systems, the first approach is a W/O/W ESE method in which the water-soluble drug is dissolved in an
inner aqueous phase prior to emulsion in an oil phase.
In a pilot study, fluorescently labelled dextran was used as a hydrophilic model drug to investigate the
W/O/W ESE technique to provide drug-loaded PLGA microspheres. For this aim an oil phase comprising
of DCM was chosen, due to its fast volatility. Furthermore, a high polymer concentration (20% PLGA)
was investigated to induce a rapid solidification to prevent diffusion of the aqueous dextran solution
into the external phase. The total amount of particles achieved by this method was 630 mg (63 %) with
the particles between 57 µm and 186 µm. The mean-diameter of particles resulted in 107 µm (Fig. 13).

Figure 13. Fluorescent micrograph of the PLGA microspheres loaded with rhodamine B isothiocyanate-dextran.

Fluorescent microscopy could confirm the incorporation of rhodamine B isothiocyanate-dextran into
the PLGA microspheres. Taken the result of this pilot experiment into account, further studies were
investigated to prepare LEV-loaded microspheres using the double emulsion method. The W/O/W
emulsion of LEV provided PLGA microspheres with a mean diameter around 20 µm. However, the
analysis of the drug loading efficiency revealed no entrapment of the hydrophilic drug into the PLGA
microspheres. As described by Viry et al., the high range of solubility of LEV in common organic solvents
used as the oil phase in the emulsion process could complicate encapsulation of the drug into the
polymeric system (Fig. 14) [96]. During the emulsification of the inner water phase into the oil phase,
the drug can easily pass into the organic phase and finally diffuse into the outer aqueous phase.
Furthermore, LEV has a low molecular weight which additionally supports a rapid diffusion of the drug
into the medium.
To improve the encapsulation of LEV into PLGA microspheres, we further investigated some
modifications of the emulsion process by either decreasing the solubility of the drug into the oil phase
or preventing diffusion of the drug into the outer aqueous phase. To reduce drug-diffusion into the oil
phase, EA was investigated. In addition to the lower solubility of LEV in EA compared to DCM, the use
of EA as the oil phase has also benefits regarding the product approval by regulatory agencies. As
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previously described by Sah et al., EA is regarded as one of the most beneficial organic solvents with
respect to patient safety [97]. However, the high solubility in water as well as the high boiling point are
the main drawbacks of EA for its use in the W/O/W ESE process. As mentioned by Meng et al., the
high solubility of EA in the aqueous phase leads to a rapid diffusion of EA from embryonic
microdroplets into the external water phase during re-emulsification which can cause the precipitation
of the polymer instead of the formation of microspheres [86].
Taken the above-mentioned considerations into account, it was chosen to investigate a modified
W/O/W ESE procedure, which was previously described by Meng et al. and includes an additional
preliminary partially solidification step. Due to the addition of a small amount of another external
aqueous phase (W3), a slow extraction of EA from the embryonic microdroplets can be realized. In this
study Meng et al. were able to effectively restrict the coagulation of oil droplets and thus a high yield
of microspheres could be achieved [86].

Figure 14. Teas graph representation of the solubility characteristics for organic solvents of PLGA. (1: tetrahydrofuran, 2:
DCM, 3: chloroform, 4: dimethylformamide,5: EA, 6: ACN, and 7: acetone). Water and Ethanol are illustrated by asterisk. The
solubility range of LEV is illustrated by the dark area [96].

As a proof-of-concept experiment, the encapsulation efficiency of fluorescently labelled dextran into
PLGA microspheres prepared by the above-mentioned double emulsion process has been investigated.
A relatively low concentration of 8% (w/v) PLGA (75:25) was chosen to minimize polymer precipitation.
The double emulsion technique using EA provided spherical MPs without agglomeration or
precipitation of PLGA. Furthermore, fluorescent microscopy could confirm the incorporation of
rhodamine B isothiocyanate-dextran into the PLGA microspheres (Fig. 15 A).
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A

B

Figure 15. PLGA microspheres prepared by W/O/W double emulsion using EA. (A) Fluorescent micrograph of the PLGA
microspheres loaded with rhodamine B isothiocyanate-dextran from 8% (w/v) PLGA solution. (B) Increasing the polymer
concentration to 15% (w/v) and 20% (w/v), respectively, resulted in polymer precipitation (red arrow).

The pilot experiment revealed that the W/O/W double emulsion technique using EA and a slow
extraction rate provides spherical MPs and is able to successfully encapsulate the hydrophilic model
drug even though no quantitative analysis of the fluorescent dextran entrapment was undertaken.
Taken the result of this pilot experiment into account, further studies were investigated to encapsulate
LEV into the polymeric microspheres. First experiments using a PLGA concentration of 8 % and a
drug/polymer ratio of 1:10 resulted in a low encapsulation efficiency about 0.5 % of LEV into the
polymer microspheres (Table 2). Another approach investigated the increase of the polymer
concentration which should correlate with a higher drug entrapment into the microspheres. For this
aim samples were prepared with 15% and 20% PLGA concentration. The increase of the polymer
concentration resulted in a fast EA extraction which caused a rapid precipitation of PLGA prior to the
formation of microdroplets (Fig. 15 B).

Table 2. Summary of microsphere characterization at different PLGA concentrations using EA.

Concentration of
PLGA

Morphology

Drug loading efficiency (%)

8% PLGA

microspheres

0.5 ± 0.1

15% PLGA

precipitation

-

20% PLGA

precipitation

-

As illustrated in Table 2., the investigation of the modified double ESE technique using EA was
unsuccessful to provide an acceptable encapsulation efficiency of LEV into the microspheres. Despite
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the reduced solubility of LEV in the oil phase by using EA instead of DCM, the diffusion of LEV into the
outer aqueous phase was still high and significantly decreased the encapsulation efficiency of the drug.
The low drug-loading efficiency of the microspheres is unsuitable for a drug delivery system, especially
in terms of a long-term release. For this reason, another approach using a modified W/O/O double
ESD technique was investigated. This technique is mostly based on the replacement of the outer water
phase by another hydrophobic phase (O2) to reduce diffusion of the hydrophilic compound. Under all
W/O/O emulsion techniques, a mixed solvent system comprising of ACN/DCM (O1) and liquid paraffin
(O2) is well described in the literature [93, 98, 99]. By choosing an oil as the processing medium, the
solvent for the polymer needs to be immiscible with the oil (O2) while providing suitable solubility for
the polymer. Compared to most other polar organic solvents, ACN is oil-immiscible but water-miscible,
which would cause precipitation of the water/ACN phase (W/O1). Thus, to guarantee microsphere
formation, DCM is added to the polymer solution (DCM/ACN, 50:50) to reduce the polarity and to
provide a stable emulsion of the polymer solution into the paraffin oil [98].
First experiments using the above described method aimed to proof the ability to entrap fluorescently
labelled dextran into PLGA microspheres. Samples prepared with 10% PLGA concentration resulted in
the formation of agglomerated microspheres and clusters (Fig. 16).

Figure 16. Photomicrograph of the 10% PLGA formulation prepared by W/O/O double emulsion reveals agglomeration of
the MPs.

Investigations of the encapsulation efficacy of rhodamine B isothiocyanate-dextran by fluorescent
micrographs revealed no compound entrapment into the microspheres. A possible reason for that
could be the formation of porous microspheres due to the low evaporation of ACN during
emulsification. Longer solvent evaporation time correlates with decreased particle solidification and
thus can lead to porous microspheres in which the encapsulated drug can be easily washed out of the
system [82].
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Given that the pilot experiment of the W/O/O emulsion resulted in no encapsulation efficiency of
fluorescent dextran, no further experiments were undertaken to encapsulate LEV. Summarizing the
encapsulation efforts for hydrophilic LEV using the W/O/O double ESD and the W/O/W double ESE
techniques, all experiments failed to provide microspheres with an acceptable drug loading efficiency.

3.1.3 Characterization of PHT-loaded microspheres
As may be evident from the above, the encapsulation process of very hydrophilic LEV still needs further
investigations in order to establish a procedure which provides microspheres with suitable drug
loading. Additionally, the pilot experiments revealed that it is uncertain to obtain a sustained drug
release of LEV from microspheres using ESD or ESE due to the excellent solubility in both organic and
aqueous solvent. As previously mentioned, the neurosurgical implantation of such a device is related
to the high risk of intracranial infections or neurological deficits [67]. Thus, a long-term release of the
AED is one of the crucial features for an implantable collagen membrane for the treatment of epilepsy.
In pursuit of this goal we further centred our investigations on the preparation of PLGA microspheres
loaded with anti-convulsive PHT. The advantage of this drug is the low water solubility with around
32 mg/L which enables encapsulation of PHT in a single O/W emulsion as previously described by Jiang
et al. [94, 100]. To investigate the optimized PLGA concentration regarding its encapsulation efficiency
of the drug, samples were prepared using 10%, 15% and 20% PLGA (Fig. 17). PHT-PLGA microspheres
prepared by the ESE method showed acceptable PHT content in almost all particle formulations (40.6%
- 51.2%) (Table 3). Compared to the preparation of DEX-microspheres, PHT-microspheres showed a
smaller mean diameter (7.8 µm – 15.4 µm).

Table 3. Summary of PHT-microsphere characterization at different PLGA concentrations.

Concentration of
PLGA

Average particle size
(µm)

Drug loading efficiency
(%)

Yield (%)

10% PLGA

15.4 ± 4.0

40.6 ± 3.6

71.2

15% PLGA

7.8 ± 1.7

48.6 ± 6.2

62.5

20% PLGA

12.7 ± 3.7

51.2 ± 7.9

14.7
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Figure 17. Photomicrographs of the PHT-spheres prepared using an O/W emulsion from (A) 10%, (B) 15% and (C) 20% PLGA.

To assess the drug release behavior of these particle formulations, an in-vitro release study was
investigated in an aCSF (pH 7.4) solution at 37 °C for 30 days (Fig. 18). For these studies samples from
the 10% and 15% PLGA formulations were chosen as the microsphere yield from the 20% PLGA was
significantly low due to the concurrent precipitation of a high amount of polymer during emulsification.
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Figure 18 Cumulative PHT released from the PLGA microspheres during an in-vitro release study in aCSF (pH 7.4) at 37 °C (n =
3) for 30 days. (A) and (C) Quantitative release of PHT from 1 mg of 10% and 15% PLGA-microspheres, respectively. (B) and
(D) Total amount of PHT released as a percentage of the total amount of drug encapsulated into the 10% and 15% PLGAmicrospheres, respectively.

Fig. 18 represents the cumulative release of PHT from 10% and 15% PLGA microspheres about 30 days.
Both formulations demonstrated sustained release of PHT following a triphasic release pattern and
were characterized by a slight burst release. For the initial 3 days, the early stage of drug release was
dominant by dissolution of surface drug and reached 9% (10% PLGA) and 6% elution (15% PLGA) of the
total drug-loading. Between 3 and 10 days the release of PHT slowed down due to the dissolution and
diffusion of the drug from the core of the spheres into the medium. After 10 days the release of PHT
represented an almost linear release pattern for the following 20 days. This phenomenon indicates a
change from a diffusion-controlled release pattern to a combined diffusion/erosion-coupled release
mechanism due to the degradation of the PLGA microspheres [101, 102]. Another possible reason
accounting for the release profile might be the formation of open channels as a result of progressive
dissolution of the drug, which may facilitate further release of drug.
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Compared to the 10% PLGA formulation which showed 36% drug release at day 30, the microspheres
obtained from the 15% PLGA showed a reduced release rate with only 28% of PHT-elution at day 30.
With regard to the time frame available, drug release analysis was stopped after 30 days. Nevertheless,
the previous discussed results indicated a promising sustained release of anti-convulsive drug from the
microspheres. For the drug-release studies of ECC matrices, the 15% PLGA formulation was chosen due
to its more sustained drug release profile.

3.2 Electrocompaction of collagen matrices
In order to achieve a good reproducibility and suitable mechanical stiffness of the collagen matrices,
the process parameters of the ECC matrices were investigated prior to the incorporation of drugloaded microspheres.
For the electrochemical compaction of collagen, it is necessary to adjust the strength of the electrical
field applied to the monomeric collagen solution. In order to measure the current during
electrochemical compaction of collagen, an amperometric three electrodes topology was utilized
(Figure 19 A). This measurement is defined by a working electrode (Stainless-steel), where the
electrochemical reaction takes place, the reference electrode, which tracks the potential solution and
a counter electrode (Indium-tin-oxide-glass, ITO-glass), which supplies the required voltage for the
electrochemical reaction at the working electrode. Freshly dialyzed collagen solution was injected
between the stainless-steel electrode (cathode) and the counter electrode (anode) in circular silicon
rubber washers and an electrical field was applied in the range of 5 – 8 volts. Application of voltages
up to 6 V resulted in transparent films free of noticeable air bubbles which could be recovered from
the working electrode after the electrochemical process (Figure 19 B). Fig. 19 C represents a
representative current-time curve of the electrochemical compaction process of collagen. Within the
first 20 seconds a rapid decrease of the current can be observed which indicates the formation of a
high resistance within the aqueous solution due to the deposition of collagen. The initial decrease of
the current is followed by a slight increase and a final constant current assuming that no further
collagen deposition takes place (Fig. 19 C). Application of higher voltages (7 V) showed the appearance
of bubbles into the collagen matrices (Fig. 19 D). These phenomena can be explained with a strong
hydrolysis taking place in the electrochemical cell, causing an increased hydrogen formation.
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Figure 19. Fabrication of ECC matrices. (A) Image of the electrochemical cell for the compaction of collagen. (B) Highly
transparent ECC matrix recovered from the electrode after the electrochemical process. (C) Representative current-timecurve of the compaction process of collagen matrices. (D) Bubble entrapment (red arrow) into ECC matrices prepared at 7 V.

Summarizing the results indicates that the applied voltage shouldn’t be chosen higher than 6 V to
prevent a strong hydrolysis and to avoid significant air bubble formation within the ECC matrices.
To further increase the mechanical stability of ECC matrices, riboflavin was investigated as a wellknown photo-crosslinker. ECC matrices were incubated in 10 times PBS containing 0.5 mM riboflavin
for 2h and exposed to UV-light. The rheological investigation of the collagen sheets incubated with
riboflavin provided three phases in the curve progression (Fig. 20 A).
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A

B

Figure 20. Photo-crosslinking of ECC matrices. (A) Representative results of rheological testing of riboflavin induced
crosslinking of ECC matrices. Increase of the storage modulus after exposure to UV-light for 30 s at 60 s.(B) Collected ECC
matrices after photo-crosslinking.

For the first phase a constant plateau of uncrosslinked collagen was present, which established the
linear viscoelastic properties of the gel. UV-light was applied at 60 s for 30 s. During this time a definite
increase of the storage modulus was observed. This is due to crosslinking activity of riboflavin. After
UV-light exposure, a small increase of the storage module was still noticeable which might be due to
continued crosslinking or continued fibrillogenesis and physical crosslinking of collagen. Furthermore,
a slow dehydration might be occurred during UV crosslinking of the ECC matrices. However, further
experiments are required to analyze this phenomenon of ECC crosslinking.

3.3 Incorporation of microspheres into ECC matrices
The potential of the electrochemically compaction process of collagen to entrap microspheres was
investigated in a proof of principle study. 10 mg of PLGA microspheres loaded with the fluorescent
Rhodamine B isothiocyanate-dextran were added to 1 mL of the monomeric collagen solution prior to
injection between the plate electrodes and electrochemically compacted. Fluorescent microscopy was
performed to evaluate the incorporation capability of fabricated collagen matrices and could
demonstrate the existence of fluorescent microspheres entrapped into the ECC matrices (21 A).
Compared to ECC matrices prepared without the addition of microspheres, particle-loaded
microspheres demonstrated a slight turbidity of the ECC matrices (21 B).
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Figure 21. Incorporation of microspheres into ECC matrices. (A) Fluorescent microscopy of particle-loaded ECC matrix.
(B) Photomicrograph of particle-loaded ECC matrix.

3.4 Mechanical properties of drug-loaded ECC matrices
To analyze the influence of microsphere entrapment into ECC matrices regarding their mechanical
properties, tensile tests were undertaken on ECC matrices and particle-loaded (5mg/mL) ECC matrices.
The Young’s modulus of ECC matrices were calculated from the Stress-Strain curves (Fig. 22).

Figure 22. Tensile properties of ECC with and without microspheres (n=3). (A) Stress-Strain curve and (B) Tensile modulus.

The Young’s modulus of photo-crosslinked ECC matrices and particle-loaded ECC matrices was 1.11 ±
0.36 MPa and 0.73 ± 0.24 MPa, respectively. Compared to the Youngs modulus of traditional collagen
gels, which was investigated by Lopez-Garcia et al. and ranged from 1 to 28 kPa., the electrocompacted
and crosslinked collagen matrices had a 50-fold greater Youngs modulus [103]. Therefore, these results
suggested that electrocompaction and photo-crosslinking significantly improved the tensile strength
and stiffness of the collagen matrices. Furthermore, the experiment revealed that the incorporation
of microspheres into ECC matrices resulted in a significant decrease of the tensile modulus up to 25%.
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This result supported the theory that the incorporation of microspheres inhibits the self-assembly of
collagen fibres and thus results in decreased mechanical properties of particle-loaded ECC matrices.

3.5 Characterization of ECC morphology by SEM-Imaging
The microstructure of particle-loaded ECC matrices and ECC matrices without particles were
investigated by SEM to achieve an in-depth understanding of the influence of microspheres on the
assembly of collagen fibrils. The SEM micrograph of the cross-section of ECC matrices without spheres
showed a dense aligned assembly of collagen fibers (Fig. 23 A). Surface analysis of particle-loaded ECC
matrices demonstrated the microsphere exposure on the surface of the collagen sheet (Fig. 23 B).

Figure 23. SEM micrographs of ECC matrices at x23000, x600, 8500 and 23000 magnifications. (A) cross-section of ECC
matrices without microspheres, (B) surface of sphere-loaded ECC matrices, (C) cross-section of sphere-loaded ECC matrices
and (D) high-resolution of the cross-section of sphere-loaded ECC matrices.

In contrast to the cross-section of ECC matrices without microspheres, cross-section of microsphereincorporated ECC matrices revealed a more irregular microstructure (Fig. 23 C). Next to the
microspheres, the density of the collagen fibres is significantly decreased compared to the collagen
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assembly in which no spheres are present. Furthermore, Fig. 23 D demonstrates that the collagen
molecules located on the surface of the microspheres show significant loss of orientation. Given that
the strong mechanical properties of ECC matrices is based on the formation of dense and aligned
collagen fibres, SEM-images provided evidence that the microsphere entrapment interrupts the
collagen assembly and thus significantly decreases the mechanical stiffnesses of ECC matrices as
demonstrated in chapter 3.4.

3.6 Drug-release from sphere-loaded ECC matrices
Adoption of drug-loaded ECC matrices for a controlled drug delivery system greatly relies on the
release profile of the targeted drug from the collagen membrane. Depending on the medical
application either short-time or sustained long-term release is required. When looking at the drugs of
interest in this study, for anti-inflammatory DEX we aimed for 14 days drug release and for anticonvulsive PHT we focussed on sustained drug release for at least 3 months.
The first crucial step in this study was to quantify the microspheres which can be entrapped into the
collagen membrane from the aqueous solution by the electrocompaction process. To analyze drugloading efficiency of ECC matrices, samples were fabricated using 5 mg DEX-microspheres and a ratio
of DEX- and PHT-microspheres (1:1) and extracted immediately after the electrocompaction process
(Table 4).
Table 4. Drug-loading efficiency of microsphere-loaded ECC matrices

Drug-loading
(µg/matrix)

Theoretical drug-loading
(µg/matrix)

Drug-loading efficiency
(%)

ECC matrices with
DEX-microspheres
(1.6 w/w)

11.6 ± 0.9

32.6 ± 1.2

35.5 ± 2.7

ECC matrices with
DEX- and PHTmicrospheres (1:1)
(0.8 w/w)

8.1 ± 0.3 (DEX)

16.3 ± 0.6

49.9 ± 1.8

6.5 ± 0.4 (PHT)

30.9 ± 0.8

21.0 ± 1.3

Samples

As illustrated in Table 4, electrocompaction provides the possibility to fabricate drug-loaded ECC
matrices with variable drug-loading efficiency. DEX-loaded samples demonstrated a total drug-loading
about 35 %. Whereas the dual-drug-loaded ECC matrices provided 49.9 % and 21.0 % drug-loading for
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DEX and PHT, respectively. As can been appreciated from the above, DEX-microspheres seem to be
more susceptible for the entrapment into ECC matrices compared to the PHT-loaded spheres. A
possible explanation for these findings could be the size of the drug-loaded microspheres. As the
mean-diameter of DEX-microspheres was suspected to be 2-fold higher than the diameter of PHTmicrospheres, the higher surface area could facilitate the attachment of collagen fibers and thus could
increase the particle-entrapment into the ECC membrane.
To assess the drug-release behavior of ECC matrices, an in-vitro release study of single- and dual drugloaded samples were investigated in an aCSF (pH 7.4) solution at 37 °C for 12 and 14 days, respectively
(Fig. 24).
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Figure 24. In-vitro release profile from single and dual drug-loaded ECC matrices (n=3) in aCSF (pH 7.4) at 37 ⁰C for 12 and 14
days, respectively. (A) Quantitative single-release of DEX from ECC matrices. (B) Total amount of DEX released as a
percentage of the total amount of drug encapsulated into ECC matrices. (C) Quantitative amount of PHT and DEX released
from dual-drug loaded ECC matrices. (D) Total amount of PHT and DEX released as a percentage of the total amount of drug
encapsulated into ECC matrices.
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DEX-MP loaded ECC (Fig. 24 A and B) demonstrated a sustained release for 11 days following a biphasic
release pattern. After a burst release of approximately 35% on the first day, DEX-MP loaded ECC
showed a more linear release with about 550 ng released per day for the next 10 days reaching 63%
of completion. These observations demonstrate a significant change in the release pattern compared
to the single DEX-microsphere formulation, which has shown a triphasic release, reaching a steady
state at day 8 (chapter 3.1.1). Hence, it appears that the incorporation of DEX-MP into ECC matrices
can cause a more prolonged release of DEX. As shown in figure 24 C and D, DEX-release from DEXMP/PHT-MP loaded ECC matrices is hallmarked by a reduced burst release of approximately 22% on
day 1 compared to mono-DEX-MP loaded ECC matrices. However, the biphasic release pattern is
similar to the mono-DEX-MP loaded ECC matrices, reaching around 60% of completion at day 11.
PHT-release from DEX-MP/PHT-MP loaded ECC matrices revealed a high burst release with
approximately 82% drug-elution at day 1, followed by a decreased release rate for the next 8 days
(Fig. 24 C and D). After 9 days of incubation, a plateau was reached without significant drug release.
These observations reveal a dramatic change in the release pattern compared to the single PHTmicrosphere formulation, which was hallmarked by a sustained PHT-release over 30 days and a slight
burst release. Whereas for anti-inflammatory DEX, such an initial burst may be beneficial to ensure
immediate relief after implantation of the device, for local release of anticonvulsants it is associated
with several negative effects. On one hand, the release of an unnecessary large amount of
anticonvulsants leads to a shortening of the implant's life, which is particularly critical given the risks
of neurosurgical procedures. On the other hand, an initial burst release is difficult to control, and thus
high concentrations of the drug might pose a toxicological risk to the patient [104]. Adjusting a zeroorder controlled release of PHT is therefore essential for the clinical success of the device, as a
consistent level of anticonvulsant must be present at the seizure focus to consistently inhibit abnormal
electrical transmissions once they occur.
As has been demonstrated by Lee et al., hydrogel matrices with a sigmoidal drug distribution were able
to achieve an almost zero-order sustained release pattern [105]. Taken this into consideration, it would
be worthwhile to investigate a non-uniform distribution of anticonvulsant PHT within ECC matrices,
which could be easily achieved by electrocompaction of multiple layers of collagen with heterogeneous
particle-loading.
Summarizing these results, it appears that the electrochemical fabrication process might have a crucial
influence on the release pattern depending on the investigated drug. Whereas, DEX-release from ECC
matrices demonstrated slower release compared to the single microsphere formulation, PHT-release
from ECC revealed shorter elution times and was hallmarked by a high burst release. To confirm these
findings, the initial experiments require further study, for example, the influence of the electrical field
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on the drug release. A good experiment is to load the microspheres in the electrical field, using the
same condition as for electrocompaction, to analyze the influence of the voltage on the drug release
profile.
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4. Future Perspectives
Overall, the initial experiments performed in the last 10 months showed potential of electrocompacted
collagen as an implantable device for local drug delivery. As may be evident from the above, currently
the project is still in its infancy and must be followed up with more detailed characterization as well as
process optimization.

a,

Preparation of drug-loaded microspheres

As mentioned in section 3.1, all trials with the aim to encapsulate anti-convulsive LEV via ESE or ESD
failed to provide PLGA microspheres with suitable drug-loading. However, the advantage of LEV e.g.
the low dermatological hypersensitivity or the non-hepatoxicity, makes it worth to investigate further
experiments on its encapsulation ability. Electrospraying is a novel powerful method for the
encapsulation of hydrophilic drugs into polymer particles (Fig. 25). It is an electrohydrodynamic
process, in which a liquid polymer solution is injected onto a collecting plate.

Figure 25. Schematic illustration of the electrospraying setup for fabrication of microspheres with core-shell morphology
[106].

Due to the high voltage applied, the polymer solution gets stretched and forms particle droplets.
Recently, Chen et al. demonstrated the encapsulation of hydrophilic Lacosamide into PLGA
microspheres prepared by electrospraying which showed sustained drug-release over 2 weeks [106].
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b,

Optimization of drug-loaded ECC matrices

Given that the electrochemical fabrication process of drug-loaded ECC matrices caused a dramatic
change of the drug-release kinetics compared to the single microsphere formulations, further
experiments should focus on the minimization of the burst release. To assess a controlled long-term
release, experiments need to be performed to obtain a deep-understanding of the influence of the
applied voltage on the drug-release characteristics. Another approach to reduce drug diffusion could
be a layer-by-layer electrocompaction of collagen sheets, as recently described by Younesi et al. (Fig.
26) [20]. Due to the addition of outer layers of compacted collagen without microspheres, the drug
diffusion from the microsphere-loaded inner collagen layer could be slowed.

Figure 26. Layer-by-layer electrocompaction of collagen sheets (modified) [20].

c,

In-vivo study

Given the nature of the drug-release experiments, in which the release profile was determined by a
highly simplified in-vitro study, it is essential to take into account in-vivo studies. In-vivo experiments
would give the opportunity to evaluate ECC matrices in terms of its biocompatibility. A rat tetanus
toxin model of temporal lobe epilepsy could be investigated on the efficacy of drug-loaded ECC
matrices to successfully suppress seizure activity.
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5. Conclusion
In this research project, electrochemical compaction of collagen was evaluated as a potential drug
delivery system for local therapy of refractory epilepsy. Anti-inflammatory DEX and anti-epileptic PHT
were successfully encapsulated into PLGA microspheres using ESE and demonstrated sustained drug
release in an in-vitro experiment. Initial experiments have demonstrated the ability of the
electrocompaction process to incorporate drug-loaded microspheres into the ECC membranes. Tensile
tests were performed to ensure an in-depth understanding of the influence of particle-entrapment
into the ECC matrices in regards of their mechanical properties. The in-vitro release study of DEXloaded ECC matrices demonstrated a more sustained release behaviour compared to the single
microsphere formulation. The in-vitro release study of the dual drug-loaded ECC matrices revealed a
dramatic change in the release behaviour of the anti-epileptic drug. PHT-release from ECC resulted in
faster elution which was hallmarked by a high burst release. The study suggests that the
electrochemical fabrication process of ECC matrices has a crucial influence on the release behaviour
of drug-loaded PLGA microspheres. For the field to progress, it is essential to get an in-depth
understanding about the parameters which cause the change in the release pattern of microsphere
formulations. Beside this, future experiments need to consider in-vivo studies, to evaluate the
biocompatibility and efficiency of drug-loaded ECC matrices.
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German Abstract – Zusammenfassung

Mundschleimhautdefekte mit freiliegendem Kieferknochen im Rahmen von Osteonekrosen,
welche oftmals durch Langzeittherapien mit Bisphosphonaten hervorgerufen werden,
erweisen sich als ernstzunehmendes Problem im Bereich der Mund-, Kiefer- und
Gesichtschirurgie. Bei fortgeschrittener Nekrose ist eine Behandlung mit antibakteriellen
Wirkstoffen oftmals nicht zielführend und eine Teilresektion des betroffenen Knochens ist
notwendig. Um die mechanische Integrität des betroffenen Knochens zu gewährleisten,
kommen Knochentransplantate zum Einsatz, welche jedoch oftmals ein unzureichendes
Ausheilen der Wunde aufzeigen. Durch die Verwendung von Membranen, die das Implantat
vor einer bakteriellen Infektion schützen und die Regeneration des Wundgewebes begünstigen
könnte die Erfolgsrate der Behandlung gesteigert werden. In den letzten Jahrzehnten führte
das Prinzip der Guided Tissue Regeneration (GTR) zu einem Paradigmenwechsel in der
Chirurgie. Durch die räumliche Trennung langsam proliferierender Knochenzellen und schnell
teilenden Weichgewebszellen der Mundschleimhaut, in Form einer Barrieremembran kann
eine geführte Ausheilung der Wunde erfolgen.
Neue Forschungsansätze bedienen sich dabei sogenannten Elektrospinn-Verfahren und
Additiven Fertigungsprozessen um Faserstrukturen im (Sub)-Mikrometer-Bereich herzustellen.
Vor allem das sogenannte Melt Electrospinning (MES) und das daraus resultierende Melt
Electrowriting (MEW) zeigen ein hohes Applikationspotential. Letzteres ermöglicht die exakte
Positionierung solcher Fasern und somit die Produktion komplexer 3D-Strukturen.
Die Zielsetzung dieser Masterarbeit ist die 3D-Fertigung einer funktionsfähigen Membran
mittels MES und MEW für die Zwecke der GTR im Bereich der Mund- Kiefer- und
Gesichtschirurgie. Die entstehende Membran soll dabei im Wesentlichen aus zwei Teilen
kombiniert werden. Zum einen soll mit dem Elektrospinn-Verfahren eine bakteriendichte
Schicht hergestellt werden; im zweiten Schritt soll das Aufdrucken definierter Faserstrukturen
im Sinne der GTR erfolgen.
Im ersten Schritt der Arbeit wurde die Herstellung der bakteriendichten Membran fokussiert,
wobei verschiedene Prozessparameter (Temperatur, Düse, Kollektordistanz und geschwindigkeit) erforscht wurden um ein dichtes Netzwerk von Submikron-Fasern zu
generieren. Mit den optimierten Prozessparametern und einem neu-entwickelten
2

Düsensystem, indem eine Akupunkturnadel verarbeitet wurde, konnten Nanofasern von
193 nm ± 146 nm erzielt werden. Gemäß unserm besten Wissen sind dies die kleinsten Fasern,
die bisher mittels MES-Verfahren produziert wurden. Eine erfolgreiche Untersuchung auf die
Bakteriendichtigkeit konnte aufgrund limitierter Ressourcen und dem verfügbaren Zeitraum
nicht umgesetzt werden. Desweitern konnte die Verbindung der elektrogesponnenen
Komponente mit definierten Faserstrukturen anhand eines benutzerdefinierten DoppelDruckkopf-Systems durchgeführt werden. Dabei wurden Unterschiede bei der Reihenfolge des
Druckverfahrens der einzelnen Komponenten deutlich gemacht.
In der vorliegenden Arbeit konnte die Herstellung einer Membran mittels 3D-Druckverfahren
demonstriert werden, die hohes Potential für weiterführende Studien aufweist.
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1. Introduction
1.1 Challenges in operative dentistry - osteonecrosis of the jaw
The treatment of several bone defects such as osteoporosis, bone metastasis and multiple
myeloma, often involve the therapeutic use of bisphosphonates [1, 2]. Despite the efficacy to
successfully treat bone disorders, studies of the past decades revealed the impact of
bisphosphonates therapies to cause exposed and necrotic bones in the mandible and
maxilla [3]. Osteonecrosis of the jaw (ONJ) is a severe condition hallmarked by the death of
bone material (Figure 1).

A

B

Figure 1. Appearance of necrotic bone and the surgical treatment. (A) Marginal resection of the necrotic bone in the
mandible. (B) Radiograph of the mandible after bone resection [1].

Disruption of the hierarchical structure of the bone leads to joint pain and loss of function [4].
The adequate treatment strategy of bisphosphonate-related ONJ still remains controversy. First
approaches are focused on the use of antibiotic agents and anti-bacterial mouth rinse [5]. If the
disease persists despite long-term drug treatment, the resection of the necrotic bone is
favourable. To guarantee the mobility of the patient, implants are used to ensure the
mechanical stiffness of the jaw. Unfortunately, in some cases implant failures occur due to
insufficient tissue regeneration or bacterial infections. To overcome this drawback, membranes
are investigated which are able to enhance tissue regeneration and prevent bacteria infiltration
towards the implant.
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Box 1. A glance on bone remodelling
The term bone remodelling includes the removal and repair of damaged bone to guarantee its
mechanical integrity and mineral homeostasis. Coordination of this accurately clocked
mechanism is given by molecular mechanisms and several cellular participants, such as
osteoclasts, osteoblasts and osteocytes [6]. While the exact mechanism of bone remodelling is
still unknown, it is well established that in the beginning osteoclastic precursors become
activated and undergo differentiation into osteoclasts. This cell type is capable of resorbing a
discrete area of mineralised bone matrix, which is directly followed by a reversal phase in which
osteoblasts, derived from osteoprogenitor cells, migrate into the resorption lacuna [7]. In the
so-called formative phase, osteoblasts start to place unmineralised bone material (osteoid) into
the resorption lacuna. If an adequate amount of osteoid is deposited, mature osteoblasts will
undergo cell death or will be embedded into the mineralised matrix in which differentiation
into osteocytes takes place. If new circles of bone remodelling are necessary, osteocytes will
start the recruitment of osteoclasts to dispose damaged bone material.

1.2 Membrane technology for guided tissue regeneration
1.2.1 The principle of guided tissue regeneration
While in the early beginnings of clinical dentistry, surgery procedures were focussed on the
repair instead of the full reconstitution of the lost tissue, over the last four decades, important
steps have been made to initiate tissue regeneration. The origin of guided tissue regeneration
(GTR) goes back to a series of studies starting from the early 1970s which were able to
demonstrate the regenerative capability of periodontal tissue components [8]. Following these
findings, it was hypothesised that by consequently separating fast proliferating soft tissue cells
from slowly separating bone cells, superior tissue regeneration could be achieved [9]. First
proof-of-concept studies presented by Nyman et al. and Gottlow et al. revealed the formation
of new connective tissue using GTR technology [10, 11]. Periodontal defects were created in an
animal-model and membranes were inserted over the denuded root surfaces of the teeth. By
implantation of the physical barrier into the defect, the oral epithelium and the gingival
9

connective tissue were prevented to interrupt the healing process by cells deriving from the
periodontal ligament (Figure 2).

A

B

C

Figure 2. Design and outcome of the periodontal GTR study. (A) Resection of the crown of the tooth after root
instrumentation. (B) Membrane insertion prior to flap replacement. (C) Incorporation of the membrane (arrowheads) within
newly formed bone tissue (adapted from Gottlow et al. [10]).

As a result of this study, test surfaces exhibited significantly more new attachment than the
control surface, providing evidence that the use of an occlusive membrane favoured
repopulation of the wound area from cells of the periodontal ligament. These outcomes paved
the way for a paradigm changes in clinical surgery.

1.2.2 Membranes for guided tissue and bone regeneration
Since the first GTR technology was applied to humans based on a cellulose acetate laboratory
filter, the range of processable materials suitable for medical application constantly expanded
ending in a great variety of membranes each offering clear advantages and disadvantages. As
described by Scantlebury et al., barrier membranes need to fulfil a range of essential
requirements to be used in medical application. As already mentioned previously, membranes
for GTR should provide space-making capabilities to ensure cell migration into the wound area
for a certain time duration. Furthermore, biocompatibility, which means that the membrane
does not trigger any adverse effect when interacting with the host tissue, is another crucial
factor. Another important aspect is the mechanical strength of the barrier to prevent
10

interruption of the healing process due to underlying blood clots. To avoid removal surgeries
of the implant, an adequate degradability of the membrane which matches the regeneration
rate of the tissue is also highly favourable [12].
In general barrier membranes, which have been used in clinical applications can be grouped as
resorbable or non-resorbable membranes (Table 1). Poly(tetrafluoroethylene) (PTFE) were the
first non-resorbable membranes [13]. Today commercially available PTFE membranes are
divided in high-density PTFE and titanium-reinforced high-density PTFE. PTFE membranes are
hallmarked by these excellent stability characteristics providing space for tissue regeneration
and integration and this good biocompatibility. The main drawback of non-resorbable
membranes is the need for removal surgeries which is attended by pain for the patients, but
also seen from an economic perspective, additional procedure costs. To address this limitation,
first resorbable membranes were developed in the late 1980s, consisting of commercially
available polyesters (e.g., poly(glycolic acid), poly(lactic acid) (PLA) and poly(ɛ-lactone) (PCL)).
These synthetic biomaterials undergo polymer erosion through the cleavage of hydrolytically
sensitive bonds and demonstrate degradation rates ranging from some month to several years.
Early investigations of these biomaterials also proofed their superior biocompatibility [14, 15].
Despite the resorbable properties, an important concern for the use of resorbable membranes
is the unpredictable resorption time and the degradation rate, which correlates with decreased
mechanical strength by time [9].
Over the decades, nature-derived polymers are highly recognised alternatives to synthetic
polymers due to their superior cell affinity [16, 17]. Most studies were undertaken on
membranes consisting of collagen, derived from human skin, bovine tendon or porcine skin [9].
Despite their superior biocompatibility, collagen membranes present several limitations. It has
been shown that these membranes are prone to bacteria colonisation which results in rapid
degradation of the membrane by proteolytic enzymes and the loss of its mechanical
strength [18]. Furthermore, there is a certain risk to transmit diseases to the patient by using
animal-derived collagen [19].
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Table 1. Currently commercially available barrier membranes for GTR (modified from Bottino et al. [13]).

Resorbability
Non-resorbable

Resorbable synthetic

Resorbable collagen-based

Commercial Name

Composition

Degradation
rate

Cytoplast TXT-200

high-density PTFE

Nondegradable

Cytoplast Ti-250

Titanium-reinforced highdensity PTFE

Nondegradable

Resolut LT

Poly-DL-lactic/co-glycolic
acid

5 – 6 months

Vicryl

Polyglactin 910

ca. 9 months

AlloDerm

Collagen Type-I derived
from cadaveric human skin

ca.16 weeks

BioMend Extend

Collagen Type-I derived
from bovine tendon

18 weeks

To date, a new strategy emerged in the field of GTR, investigating the incorporation of growth
factors and bioactive molecules into barrier membranes [20-22]. For instance, Miron et al.
demonstrated increased osteoblast proliferation and differentiation on a collagen barrier
membrane soak-loaded in bone morphogenetic protein 2 and transforming growth factor
ß1 [23]. Moreover, a commercially available enamel matrix derivative has provided increased
periodontal regeneration by stimulating the formation of periodontal tissues [24].
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1.2.3 Anti-bacterial approaches in membrane technology
Besides material considerations, studies of the last decades revealed the impact of pathogenic
microorganism on the success of GTR strategies. It has been shown that adequate tissue
regeneration cannot be achieved for barrier membranes which were implanted into bacterial
infected areas [25, 26]. Furthermore, unresisted bacteria colonisation of the barrier membrane
implies a high risk for the infection of underlying tissue. Due to bacteria infiltration, implant
failures can occur which require the need for removal surgeries [27, 28]. As hallmarked by
Selvig et al., to ensure patients safety and to guarantee treatment success, it is essential to
control the pathogenic microorganism in the implantation site [29].
To address this issue, research over the last years aimed to create anti-bacterial properties into
the membranes [30-32]. For instance, Kenawy et al. reported the incorporation of tetracycline
into poly(ethylene-vinyl acetate) (PEVA) and 50/50 PLA/PEVA fibrous mats by blending. In vitro
release of these membranes demonstrated smooth release of the drug over about 5 days [30].
The efficacy of membranes blended with bactericidal metronidazole to successfully reduce
bacteria growth and biofilm formation has been quantitatively assessed by Bottino et al. [33].
Another approach has been focussed on the surface modification of commercially available
biodegradable membranes to create anti-bacterial properties. Membranes were mineralised
with

zinc

phosphate,

which

resulted

in

significant

decrease

of

Actinobacillus

actinomycetemcomitans activity compared to non-mineralised control groups [34]. Another
approach investigated ultrafine PLA fibres consisting of silver nanoparticles [35]. These fibres
demonstrated the reduction of microorganism of about 98% and 94% against Staphylococcus
aureus (S. aureus) and Escherichia coli, respectively.
Despite promising results in terms of anti-bacterial capabilities of GTR membranes, these
studies have failed to provide sustained long-term release of anti-bacterial agents. Besides
optimisation and development of biomaterials, recent advancements of fabrication
technologies that enable the processing of complex polymer structures through more
controlled and precise deposition of polymeric material could lead to a new paradigm of local
drug delivery systems through offering high versatility in controlling drug release profiles,
personalised customisation and multi-drug incorporation.
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1.3 Additive manufacturing
Additive manufacturing (AM), also known as rapid manufacturing or rapid prototyping, is
defined as the process of layer by layer deposition of material to make 3D objects according to
a computer aided design model. This direct transformation offers the possibility of producing
structures with complex geometry, which cannot be accessed by conventional material
removal fabrication techniques. Furthermore, AM is highly suitable for small scale production,
especially personalised manufacturing. Additionally, 3D printing approaches offer the
possibility to process in a solvent-free fabrication mode, which implicates advantages for
approval by regulatory agencies. These benefits have allowed the steady growth of AM
techniques in biomedical application, especially in terms of tissue engineering (TE) and
customised implants [36, 37].

1.3.1 Melt electrowriting
Recently, a novel electrohydrodynamic direct writing approach, defined as melt electrowriting
(MEW) emerged in the field of AM [38]. Technically MEW evolved from the well-established
electrospinning process, which has been intensively studied to produce micro/nanofibrous
structures for a broad range of biomedical applications (Figure 3) [39-41].

Figure 3. Fabrication modes to produce random non-woven polymer fibres (electrospinning) and accurate layer-by-layer
deposition of polymeric fibres (MEW) [42].
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In general, electrospinning involves the injection of a polymer solution or melt through a nozzle
under high electrical field. The polymeric material at the tip of the spinneret forms a droplet.
When the viscosity of the polymer solution is above a threshold, the ejected polymer will not
break down as microdroplets due to Raleigh instabilities, resulting in continuous non-woven
fibre deposition on the collector substrate [43, 44]. Due to the high viscosity, melt
electrospinning (MES) typically provides fibres ranging from 5 to 40 µm whereas solution
electrospinning typically results in submicron fibres. However, as reported by Dalton et al., MES
also offers the possibility to produce submicron fibres [45]. Despite clear advantages, compared
to solution electrospinning, MES has only recently been investigated [46]. For instance, MES
allows processing in a solvent-free mode, thus samples do not need to degas but also solvent
accumulation during processing can be avoided [47]. Moreover, fibre diameters can be easily
adjusted by the flow rate [48]. To date, it has been shown that a great variety of polymers with
a long history of clinical use can be processed by MES [49-51].
Several studies have demonstrated the potential of electrospun (nano-)fibres in the field of TE
to provide scaffolds which mimic the fibrinous structure of the extracellular matrix resulting in
increased cell adhesion and proliferation [52-54]. However, the low pore sizes occurring due to
the random deposition of fibres prevent cells to penetrate the mesh. As highlighted by Mikos
et al., scaffolds need to provide pore sizes of at least 20 µm to initiate cell invasion and
growth [55]. Over the last decades several techniques, such as electro-conductive collectors,
fibre deposition onto liquid, electric field manipulation and rotating devices were investigated
to increase the control of fibre placement during electrospinning [56-59]. However, despite
these approaches, accurate fibre deposition, as provided by AM has not been reached. In terms
of MEW, the predictable deposition of fibres has been achieved by introducing a laterally
translating collector system into MES (Figure 4).
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B

C

Figure 4. Fabrication mode of MES and the resulting fibre morphology. (A) Schematic showing of the MES jet depending on
the speed of the collector. (B) Random deposition of electrospun fibres. (C) Accurate deposited fibres via MEW [60].

If the collector speed exceeds the speed of the jet (sj), fibres are deposited from the region of
the jet where the flight path is straight. The control of fibre deposition enables the layer-bylayer fabrication of scaffolds with complex geometry and patterns [60-63]. Over the last years,
multiple studies have demonstrated the potential of MEW to provide scaffolds with pore sizes
suitable for TE applications [47, 64, 65]. For instance, Farrugia et al. were able to fabricate meltelectrowritten porous PCL scaffolds with an interfibre distance (46 ± 22 µm) suitable for cell
infiltration. Due to the high porosity of these scaffolds dermal fibroblast were able to penetrate
and a 3D fibroblast scaffold with full cellular penetration has been achieved after 14 days
in vitro [66]. More recently, Castilho et al. investigated the potential of MEW scaffold in cardiac
TE. It has been demonstrated that cardiac progenitor cells (CPCs) showed improved alignment
and growth along these highly ordered microfibre scaffolds (Figure 5) [67].
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Figure 5. Fabrication of MEW scaffolds for cardiac TE. (A) MEW device set-up. (B) Well-organised MEW scaffolds. (C) Fibre
scaffold infiltrated with CPCs/collagen hydrogel [67].

1.3.2 Multiphasic scaffolds
As highlighted by Dalton et al., the combination of AM and electrospinning technologies can
have a significant effect on future scaffold designs [68]. While AM provides scaffolds with high
mechanical stability and offers the fabrication of higher constructs, it also includes lower
resolution limits. In contrast, solution electrospinning results in fibres ranging in the nanometre
scale, however this technology is unable to accurately deposit fibres. Early efforts to combine
AM and electrospinning were reported in 2008 by three different groups [69-71]. For instance,
Park et al. developed a nano- and microhybrid process consisting of direct polymer melt
deposition and electrospinning [71]. The resulting 3D scaffold demonstrated an open porous
network and a biocompatible ultrafine inner architecture (Figure 6).
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D

Figure 6. Bimodal scaffold. (A) Photograph of the resulting 3D structure. (B) Hybrid basic unit layer comprising of microfibres
and the electrospun submicron fibres. (C and D) Magnified images of (B) [71].

This scaffold morphology allowed cell invasion while cell adhesion and proliferation were
improved by the incorporated ultrafine fibres. In contrast to bimodal scaffold in which
microfibrous and nanofibrous components are distributed throughout the 3D design,
multiphasic scaffolds usually consist of different regions of pore size and porosity [68]. Due to
the different morphology, scientists aimed to provide an adequate environment for different
cell types, which are needed to build new functional tissue interfaces. As an example of this
strategy, Vaquette et al. evaluated the potential of a biphasic scaffold to simultaneously
regenerate alveolar bone and periodontal ligament complex [72]. In this study, an electrospun
component was used as a support material for the adhesion of periodontal ligament cell sheets,
whereas a fused deposition modelling scaffold was fabricated to provide space maintenance
for the bone component.
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2. Aims and objectives
As can been seen from the preceding literature investigations, despite of a broad spectrum of
different materials and fabrication methods investigated, there remains the need for advanced
GTR membranes to fulfil the essential aspects of oral and maxillofacial surgery:

I, Sufficient handling for the use in surgery
II, Appropriate biodegradability
III, Good mechanical stiffness to ensure placeholder-capacities
IV, High biocompatibility
V, Bacteria-tightness and anti-bacterial efficacy
VI, Surface modification with GTR capacities

The objective of this work was to investigate the combination of MES and MEW to fabricate a
biphasic scaffold in a one-step process using a custom-build double-headed MEW device. By
combining the power of these techniques, we assume that defined features of GTR could be
addressed (Figure 7). MES parameters, especially the influence of temperature, will be
investigated in order to produce a highly dense network of small fibres which could have the
potential to prevent bacteria infiltration. To achieve this, we will further investigate a modified
nozzle system, consisting of an acupuncture (AP) needle which is mounted within a nozzle.
Building on this, melt electrowritten box structures, offering pore sizes suitable for cell
infiltration will be investigated. Finally, the combination of both components will be explored
using the optimised processing conditions. Surface morphology of the resulting biphasic
scaffold will be analysed and evaluated.
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Figure 7. Concept of the multiphasic scaffold. B represents the melt electrospun component, which could prevent bacteria (blue
circles) penetration towards the implant. A and C represent melt electrowritten box scaffolds with adjusted box width suitable for
cell infiltration.
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3. Materials and methods
3.1 Materials
All samples were produced with a good-manufacturing-practice-manufactured PCL, which has
been purchased from Corbion, Inc. (PURASORB PC 12, Lot#1412000249, 03/2015, Gorinchem,
Netherlands) and has been stored as described elsewhere [73]. AP needles and the 30G and
22G flat-tipped nozzles were cut to the appropriate length (Leonidov, Mainz, Germany) and
(Carl Roth GmbH and Co. KG, Karlsruhe, Germany) respectively. The AP needle was then
embedded within the nozzle by slightly crimping the uppermost part of the nozzle, so that the
end of the AP needle is level (protrudes 3 to 1 mm) from the end of the nozzle.

3.2 MEW device
All studies were performed with a custom-built double-headed MEW device (Figure 8). An x-y
slide system (Bosch Rexroth AG, Lohr am Main, Germany) was attached on an aluminium plate
with connection to programmable logic controllers (Bosch Rexroth AG, Lohr am Main,
Germany).

Figure 8. The double-headed MEW device used in this study.
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This system was embedded within an aluminium frame box (68x60x80 cm) with polycarbonate
windows. Material for processing was filled into glass syringes (Sigma-Aldrich, St. Louis, USA)
and placed within an electrical heater and connected to a controllable air pressure system
(Bosch Rexroth AG, Lohr am Main, Germany). A positive high voltage (HV) source (LNC 100005 pos, Heinzinger Electronic GmbH, Rosenheim, Germany) was linked to the HV electrode at
the spinnerets and the negative HV source (LNC 10000-5 neg, Heinzinger Electronic GmbH,
Rosenheim, Germany) was connected to a 200x175 mm stainless steel platform on which the
collector was mounted [73].

3.3 Processing
MES was investigated at 22 ±2 °C and a relative humidity of 40 ±10 %. The temperature of the
PCL melt for standardised conditions was set to 80 °C unless mentioned otherwise. In general,
polymeric material was used within 7 days. The acceleration voltage (composed of the
difference between negative voltage on the collector and the positive spinneret) was kept at
12 kV for electrospinning conditions and 6 kV for MEW, if not specifically stated otherwise.
Patterning of the deposited material was generated using G-codes. Glass slides (26x50 mm)
were used as collector material.

3.4 Scanning electron microscopy (SEM) and light microscopy
Samples were imaged using a stereomicroscope (Discovery V20, Carl Zeiss Microscopy GmbH,
Göttingen, Germany). SEM of the membranes and scaffolds was investigated using a
Crossbeam 340 SEM (Carl Zeiss Microscopy, Göttingen, Germany) equipped with GEMINI eBeam column. Prior to SEM imaging, samples were sputter coated with a 3 nm layer of platinum
(Leica EM ACE600, Wetzlar, Germany). ImageJ software was utilised to determine fibre
diameters of the electrospun and melt electrowritten samples. In case of the electrospun
membrane, for each varied parameter three samples were analysed by imaging a random
region of each sample. To quantify electrospun fibre diameters, SEM images were overlaid with
a grid and all overlapping fibres were counted manual (Figure 9). For the MEW scaffolds,
measurements were taken at 20 random regions of the microscopic image. Mean diameter,
median and standard deviation (SD) was calculated.
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Figure 9. Determination of fibre diameters by overlaying a grid.

3.5 Bacterial test
Bacteria-tightness of membranes were tested against gram-positive bacteria (S. aureus) using
a self-designed diffusion assay. The tryptone agar solution was prepared by weighting 2 g yeast
extract (AppliChem, Darmstadt, Germany), 4 g tryptone (AppliChem, Darmstadt, Germany), 2 g
NaCl (Sigma Aldrich, St. Louis, USA) and 6 g agar (AppliChem, Darmstadt, Germany) into 400 mL
of double distilled water and sterilised at 120 °C in the autoclave for 20 min followed by casting
onto disposable sterilised petri dishes (90 mm) for solidification. S. aureus was cultured at 37
°C for 24 h in a sterilised lysogeny broth (LB)-medium and then diluted with LB-medium to a
concentration of around 1 x 105 colony forming units/mL. Three membranes were inserted into
custom-built steel rings and the edges were fixed using a glue (Adchem, Wendelstein,
Germany). These constructs were set into 6-well plates. 1 mL of the bacteria solution was
injected on top of the membrane while 3 mL of LB-medium was added into the outer plate.
Plates were incubated at 37 °C for 24 h. On the following day 100 µL were taken from the
bacteria solution and from the outer LB-medium and spread onto agar plates using sterilised
glass marbles. Plates were than incubated for another 24 h and bacteria growth on the plates
were examined to evaluate diffusion of S. aureus through the membrane.
To investigate cytotoxicity of the different materials used in this study, S. aureus solution was
spread onto agar plates. Membranes + 20 µL LB-medium, membranes + 20 µL phosphatebuffered saline (PBS), membranes + glue, pure glue and steel rings were gently pressed onto
the agar plates. Samples were incubated at 37 °C for 24 h and the zone of inhibition of S. aureus
growth was macroscopic evaluated.
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4. Results & discussion
4.1 Investigations on the electrospun membrane
In this chapter initial experiments are described and discussed with focus on the preparation
of the electrospun membrane of the biphasic scaffold. Different fabrication parameters are
investigated with the aim to fabricate high quality fibres with minimum fibre diameter.

4.1.1 Establishing electrospinning on the double-headed MEW device
The literature investigating MES reveals a broad variation in the fabrication parameters,
specifically in terms of the collector distance and the applied voltage. To assess a standardised
electrospinning setup on the custom-built MEW device, first studies were performed to
investigate the influence of the applied voltage regarding the collector distance. For this aim a
30G needle was used and the polymer temperature was kept at 80 °C while a minimal pressure
of 0.1 bar was adjusted. Collector distances of 10 mm, 15 mm and 20 mm were investigated.
When applying a voltage of at least 9 kV to a collector distance of 10 mm, formation of a Taylor
cone was observed, and electrospinning occurred within 2 min onto glass microscope slides
(Figure 10). By increasing the collector distance to 15 mm, higher voltages (12 kV) were
necessary to initiate fibre deposition. However, MES at a collector distance of 15 mm was
unstable and resulted in jet breakup. By increasing the collector distance to 20 mm, even with
maximum voltage (17 kV), no Taylor cone formation was observed.

A

B

Figure 10. Electrospinning setup. (A) Fibre deposition onto glass microscope slides at a collector distance of 10 mm. (B)
Taylor cone formation at the top of the nozzle. Scalebars: A: 1 mm; B: 300 µm.
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Overall, these results indicate that for our work, a collector distance of 10 mm is most suitable
for MES as no jet breakup was observed. Furthermore, this collector distance allows decent
voltages with no need to apply maximum voltage (17 kV). It has been shown that at high
voltages arcing occurs, especially when moving the spinneret between two microscope slides.
Consequently, continuous arcing can result in lower fibre uniformity but also can lead to severe
instrument damage. However, it also has been demonstrated that a high electrical field
provides higher uniformity of the deposited fibres [73]. Taken these considerations into
account, it has been chosen to continue following experiments with an applied voltage of 12 kV.
This was the maximum value which was able to be used at a collector distance of 10 mm
without arcing.
As illustrated in Figure 10, compared to solution electrospinning which typically shows whipping
of the jet, jet from the polymer melt showed almost linear deposition characteristics. This
finding is in line with observations from different studies. As declared by Dalton et al., bending
of molten polymer jets might be occur next to the collector, but is not regarded as an absolute
phenomenon of MES [45, 74]. Furthermore, it is important to notice that the jet flow was
inconsistent within the first 10 min. To ensure the production of high quality fibres we thus
used a sacrificial pattern prior to the desired pattern which has been described previously by
Hrynevich et al. [75].

4.1.2 Membrane design
By moving the collector during MES, a circular membrane was designed using G-code. As
illustrated in Figure 11, the first step of the pattern is a clockwise full movement by a certain
radius. After completion of the circle, the jet moves towards the centre. At this point, the next
circular movement is performed.
The efficacy to fabricate uniform membranes with the above described pattern mostly relies
on the spacing between two circular movements and the adjusted collector speed. In our study
the distance between the circular patterns was set to 50 µm. This distance seemed to be the
maximum resolution of the system. Furthermore, by using spacings smaller than 50 µm
electrostatic repulsion could occur between the fibres leading to uncontrolled fibre deposition.
However, to ensure overlapping of the circles we mainly focussed on the optimisation of the
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applied collector speed. For this aim, three different speeds (1000, 100 and 10 mm/min) were
investigated (Figure 12).

A

B

C

Figure 11. G-code pattern for the electrospun membrane. (A) Clockwise circular full movement. (B) Spacing line towards the
centre. (C) Repeated clockwise circular full movement.

Samples prepared with a collector speed of 1000 mm/min resulted in an almost transparent
monolayered membrane with a strand width of around 25 µm (Figure 12). Due to the lack of
overlaps between the circles, it was not possible to detach the sample from the glass slide.

A

B

C

D

E

F

Figure 12. Membranes fabricated at different collector speeds. (A and D) 1000 mm/min. (B and E) 100 mm/min. (C and F)
10 mm/min.
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By decreasing the collector speed to 100 mm/min, more material was deposited on the
microscope slide, which lead to a non-transparent membrane. Compared to the fibre strands
prepared by 1000 mm/min, deposited fibres at 100 mm/min resulted in a 4 to 5-fold increase
of the strand width and overlapping of the circles. Nevertheless, these membranes also
revealed gaps, where no polymeric material was deposited. When slowing down the collector
movement to 10 mm/min, a membrane was obtained in which no gaps between the fibre
strands have been observed. The connection of the single fibrous layers resulted in a uniform
membrane which was able to detach with tweezers without damage. Interestingly, these
samples have shown a brighter spot in the centre of the membrane, indicating that less material
was deposited at this point. To address this issue, an additional G-code has been inserted into
the pattern which provided pausing of the collector movement for 60 s when the jet was
standing above the centre point to increase material deposition (Appendix A).
Ultimately, this study has demonstrated that with adequate deposition times (10 mm/min)
overlapping and fusion of the single fibre strength can be achieved which has resulted in a
macroscopic uniform membrane. Nevertheless, these primary observations need to be
followed up by more detailed characterisation of the membrane morphology.

4.1.3 Effect of temperature on the fibre diameter
Keeping the end-goal in mind, one of the most essential requirements of the electrospun
membrane is the formation of a dense network of submicron fibres. The electrospinning
temperature has a profound effect on the fibre diameter due to the change in the viscosity of
the fluid. To determine the optimal processing temperature which results in the smallest fibre
diameters, five different values were investigated (80, 100, 120, 140 and 160 °C) while the
nozzle size and the applied pressure were kept constant (30G and 0.1 bar, respectively). The
surface morphology and the fibre diameter were determined by SEM micrographs.
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Figure 13. Representative SEM image of the melt electropun membranes prepared at 80 °C. (A) Time-dependent fibre
pulsing. (B) Magnified image of (A). (C) Fibre morphology. Scalebars: A and B: 200 µm; C: 2 µm.

As illustrated in Figure 13, samples fabricated at a processing temperature of 80 °C
demonstrated constant fibre deposition. However, it has been noticed that at decent time
intervals fibres were deposited with significant higher fibre diameters (Figure 13 B). This finding
is in line with the work of Hochleitner and colleagues, who found a time-dependent fluctuation
of the mass flow, referred to as pulsing [73]. As has been demonstrated, these flow instabilities
can be caused by changes in the feeding pressure or the acceleration voltage. As the applied
pressure was kept constant during the experiment, it can be assumed that in our study fibre
pulsing has been occurred by changes in the strength of the electric field. It is likely that through
the excess of deposited material, shielding effects have been occurred, resulting in a decrease
of the acceleration voltage. Analysing the SEM micrographs revealed fibre diameters of 339 ±
191 nm (average ± SD) with relatively large deviation due to the instabilities described above.
When increasing the temperature to 100 °C, significant changes of the membrane morphology
have been observed. Membranes prepared at 100 °C were characterised by an inconsistent jet
flow resulting in jet breakup at random spots (Figure 14). It is also important to notice, that the
increased temperature resulted in some regions where molten fibres have been deposited.
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Furthermore, increasing the temperature correlated with more pulsing. As a result, the
measurement of the fibre diameter provided a higher mean diameter (493 nm) with dramatic
increase of the SD (842 nm) (Figure 15). These observations can be explained by the decrease
of the viscosity resulting in higher flow rates of the polymer melt. As has been noted earlier by
Dalton et al., MES typically results in the most consistent fibres when the flow rate is relatively
low [76].

A

B

C

[
Figure 14. Representative SEM image of the melt electrospun membranes prepared at 100 °C. (A) Unstable fibre deposition
on the microscope slide. (B) Pulsing phenomena. (C) Magnified image of (B). Scalebars: A: 200 µm; B: 10 µm; C: 2 µm.

In general, a good tool to evaluate the strength of the fluctuation of the jet flow is the
median/average ratio. As described by Hochleitner et al., a homogenous jet diameter results in
a narrow and symmetrical distribution function with values close to 1.0. If pulsing phenomena
occur the distribution functions gets more asymmetrical [73].

29

6

Outliers due to pulsing

Fibre diameter (µm)

5

4

3

2

1

0
80

80

80

100

100

100

Processing temperature (°C)

Processing temperature (°C)

80

100

Average, nm

339

493

Median, nm

285

196

SD, nm

191

842

Ratio, median/average

0.84

0.40

Figure 15. Fibre diameters at different processing temperatures.

Dramatic changes of the morphology of the melt electrospun fibres were reported by
increasing the temperature to 120 °C (Figure 16). As can be seen from Figure 16, samples have
lost the circular G-code pattern and fibres haven been deposited randomly on the microscope
slide. Moreover, the collected fibres had a very low quality with a diameter range from several
microns to some nanometres. The decrease of the viscosity also resulted in molten fibres onto
the glass slide (Figure 16 B). In comparison to solution electrospinning which relies on solvent
evaporation to solidify polymeric material, MES is determined by cooling of the polymer jet.
The results described above indicate that a processing temperature of 120°C by a given
collector
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Figure 16. Representative SEM image of the melt electrospun membranes prepared at 120 °C. (A) Unstable fibre deposition
on the microscope slide. (B) Magnified image of (A). Scalebars: A: 200 µm; B: 2 µm.

collector distance of 10 mm does not provide enough time for adequate cooling before
reaching the collector surface. In line with this finding, further increase of the processing
temperature to 140°C and 160 °C, respectively, also resulted in unstable flow rates which were
hallmarked by random fibre deposition and pulsing (Figure 17).

A

B

Figure 17. Representative SEM image of the melt electrospun membranes at different process temperatures. (A) 140 °C. (B)
160 °C. Scalebars: 200 µm.

These findings ultimately demonstrate that the processing temperature has a crucial influence
on the surface morphology of the deposited fibres. While a processing temperature of 80 °C
provided constant jet flow with some fluctuation of the flow rate, increasing the temperature
lead to more pulsing phenomena and as a consequence ended up in a complete loss of the
control of the fibre diameter.
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4.1.4 MES using an AP needle
As reported by Hochleitner et al., the fabrication of ultrafine fibres by MES depends on three
key parameters: a high electrical field, a low flow rate and a small spinneret size [42]. As
described in chapter 4.1.3, electrospinning using the smallest nozzle size (30G) available
provided fibres in the nanometre range. However, fibre diameters showed relatively high SD.
In order to achieve even smaller fibre diameters with higher quality we further investigated a
modified nozzle system, in which an AP needle (ø 300 µm) has been mounted into a nozzle
(ø 700 µm) (Figure 18).

Figure 18. SEM images of the AP modified nozzle. Scalebar: 100 µm.

As illustrated in Figure 18, the AP needle is not centred in the middle of the nozzle.
Furthermore, the tip of the AP needle is bent. It is likely that bending of the needle has occurred
by inserting the nozzle into the heating system of the MEW device.
Due to the novelty of this nozzle system, initial experiments investigated the optimal overlap
of the AP needle for MES. By macroscopic analysis of the polymer melt flow using a 3 mm
overlap of the AP needle, it has been found that higher processing temperatures of 120 °C are
required to initialise fibre deposition. It can be assumed that this phenomenon relies on
significant cooling of the polymer jet at the AP needle. As can be seen from Figure 19, when
applying pressure to the system, a polymer droplet occurs at the nozzle tip. Due to the electric
field, the polymer melt is drawn along the AP needle. When reaching the tip of the needle,
initialisation of the polymer jet onto the collector can be recorded.
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Figure 19. MES using a 3 mm AP needle. (A) Formation of polymer droplet next to the nozzle. (B) Polymer melt draws down
the AP needle. (C) Initial polymer deposition starts at the needle tip. (D) Polymer jet after stabilisation. Scalebars: 1 mm.

Analysing the morphology of the deposited material revealed the fabrication of very poorquality fibres, similar to previous observations described in chapter 4.1.3 (Figure 20).

[
Figure 20. SEM image of deposited fibres using a modified 3 mm AP nozzle system. Scalebar: 200 µm.
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To address the limitation of the processing temperature due to cooling effects at the AP needle,
an AP nozzle with reduced overlap (1 mm) was adjusted and investigated on its potential to
fabricate fibres at lower temperature (80 °C). Macroscopic observation of this novel system
showed smoother melt flow along the AP needle, compared to the 3 mm overlap and permitted
MES at 80 °C (Figure 21).

Figure 21. MES with a 1 mm AP nozzle system. (A) Fibre deposition onto the microscope slide. (B) Magnified image of (A)
(dashed line indicates start of the AP needle). Scalebars: 1 mm.

To assess which processing temperature would be most suitable to fabricate uniform fibres
using the improved AP nozzle system, similar to chapter 4.1.3, five different temperatures were
evaluated, and the surface morphology was analysed by SEM (Figure 22).
MES at 80 °C provided submicron fibres which had diameters of 834 nm ± 320 nm. When
increasing the processing temperature to 100 °C, the fibre diameter decreased to 707 nm ±
257 nm and provided higher uniformity (Figure 23). Electrospun fibres fabricated at 120 °C,
showed a significant reduction of the fibre diameter to 193 nm ± 151 nm. By further increase
of the temperature, the collected fibres revealed an increase of the fibre diameter to 519 nm
± 389 nm and demonstrated significantly more irregularities. Given the high processing
temperature, 140 °C-fibres resulted in significant fusion of the fibres. These observations are
even more distinct on fibres prepared at 160 °C. Deposited fibres were molten and completely
fused together. These results indicate that cooling of the polymer jet by a given collector
distance of 10 mm is not sufficient to provide fibres when using processing temperatures above
140 °C.
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Figure 22. Representative SEM images of electrospun membranes prepared at different temperatures. (A) 80 °C. (B) 100 °C. (C)
120 °C. (D) 140 °C. (E) 160 °C. Scalebars: 2 µm.
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Figure 23. Fibre diameters at different processing temperatures using the improved AP modified nozzle.

Overall, these pilot experiments showed for the first time that submicron fibres can be easily
fabricated using an AP modified nozzle. Compared to submicron fibres prepared with a 30G
needle (80 °C and 100 °C), these fibres demonstrated increased uniformity. It has been noticed
that the decrease in viscosity has a dramatic influence on the fibre diameter ending up to
193 nm ± 146 nm at a processing temperature of 120 °C. To the best of our knowledge these
fibres are the smallest fibres reported for MES to date.
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4.1.5 Bacteria test on the electrospun membrane
For a successful adoption of the biphasic scaffold in oral and maxillofacial surgery, it is
important to evaluate the efficacy to prevent bacteria penetration towards the implant. To
address this issue, a diffusion test was designed using gram-positive S. aureus strains as a model
bacterium (Figure 24). S. aureus represents a typical bacterium in humans, which can be found
on the oral mucosa. The bacteria solution was injected above the electrospun membrane,
which was glued on the wall of the steel ring and the bacteria penetration into the LB-medium
was investigated over a period of 24 h. On the following day samples were taken from the
bacteria solution above and from the LB-medium and were plated onto agar plates to evaluate
bacteria colonisation.

Figure 24. Bacteria diffusion test through the electrospun membrane.

Analysis of the first experiments showed that neither on the LB medium nor on the bacterial
solution plates a bacterial colonisation took place. As the positive control has shown the
existence of S. aureus bacteria, we assumed that bacteria died after injection onto the
membranes. Given that sterilisation of the membranes was performed using an ethanol
solution which was followed by drying for 2 h, it is likely that residual ethanol on the membranes
had caused the death of the bacteria. Thus, after sterilisation, membranes were washed three
times with a PBS solution to remove the residual organic solvent. Repetition of the bacteria
diffusion test including the PBS treatment, provided identical results as previously described,
showing bacteria colonisation only on the positive control.
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In order to define which part of the experiment is responsible for the bacteria death, we further
started an agar diffusion test investigating five different systems: membrane + PBS, membrane
+ LB-medium, steel ring, membrane with glue and glue (Figure 25).

A

B

D
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E

Figure 25. Results of the agar diffusion test. (A) membrane + PBS. (B) membrane + LB-medium. (C) steel ring. (D) membrane
+ glue. (E) glue.

In the case of membrane + PBS, membrane + LB-medium and steel ring, no inhibition of the
bacteria colonisation has been observed (Fig. 25 A – C). In contrast, analysing the samples of
membrane + glue and pure glue, a clear inhibition of the bacteria growth has occurred (Fig. 25
D and E). These findings ultimately demonstrate that the glue has cytotoxic properties and
caused failure of the diffusion test.
As may be evident from the findings above, to ensure the success of the designed bacteria
diffusion test an alternative glue needs to be considered which guarantees tightness between
the membrane and the steel ring but also cytocompatibility. Due to the limited resources
available and with regard on the time frame, future experiments need to follow up on the
bacteria diffusion through the electrospun membrane.
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4.1.6 Summary
In this chapter, we investigated the possibility of MES to create a dense network of submicron
fibres. Summarised, the experimental outcome of this study demonstrates a crucial influence
of the process conditions on the fibre morphology of the membrane. Especially, the processing
temperature revealed to have a major effect on the fibre diameter as well as on the fibre
uniformity. The most promising results were obtained using a novel nozzle system consisting
of an AP needle embedded into a nozzle which was able to demonstrate the fabrication of
submicron fibres. To the best of our knowledge, these are the smallest fibres prepared by MES
to date. However, there still remains the need for further improvement regarding uniformity
and standardisation of the AP nozzle system.
Despite these promising results, for a successful adoption of the membrane into clinical use
these initial experiments need to be followed up with more detailed characterisation. For
instance, an important factor is the tensile strength of the membrane to guarantee patients
safety. Unfortunately, this issue could not be addressed during this master thesis due to the
damage of the mechanical tester. Moreover, further studies need to investigate the bacteriatightness of the membrane as the designed bacteria diffusion test failed.
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4.2 Combining MEW and MES
This chapter illustrates and discusses the results from the fabrication of melt electrowritten
scaffolds and the combination with the electrospun component of the biphasic scaffold. Melt
electrowritten scaffolds are adjusted to offer suitable size for GTR and comparisons are made
between MES on top of the MEW scaffold and vice versa.

4.2.1 Fabrication of MEW scaffolds
For the GTR-active component of the biphasic scaffold, microfibre scaffolds were melt
electrowritten using G-code to produce box-shaped pores, as described elsewhere [42]. For our
study we aimed for a box width of 200 µm for cell invasiveness and different amounts of layers
were investigated, referred to 200_5L, 200_15L and 200_30L (Figure 26).
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Figure 26. SEM images of melt electrowritten scaffolds. (A and B) 200_5L. (C and D) 200_15L. (E and F) 200_30L. Scalebars:
A,C,E: 100 µm; B,D,F: 200 µm.
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The dimension of the box-shaped pores and the fibre diameter were measured from SEM
images. It has been noticed that the actual box width of the scaffold is smaller than the designed
200 µm. This is due to the fact that the G-code in general does not take the fibre thickness into
account. 200_5L and 200_15L resulted in a mean box width of 177 µm ± 5.6 µm and 181 µm ±
19.1 µm, respectively and a mean fibre diameter of 14.7 µm ± 1.4 µm and 16.3 µm ± 2.2 µm
(Table 2). While 200_5L offered regular box width, pores of the 200_15L revealed more
variation of the size. When looking at the 200_30L sample, fibre deposition was even more
uncontrolled resulting in the loss of defined box structures. This observation is in line with the
work of Brown and colleagues, who found that increased height of fibres correlates with the
loss of the deposition control due to charge accumulation on the fibres [60].
Table 2. Microfibre scaffold measurement determined from SEM images.

Scaffold

Box Width (µm)

Fibre Diameter (µm)

200_5L

177 ± 5.6

14.7 ± 1.4

200_15L

181 ± 19.1

16.3 ± 2.2

200_30L

-

18.7 ± 3.9

Overall, this study showed the ability to fabricate 3D box structures with defined box
dimensions suitable for GTR application.
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4.2.2 Fabrication of biphasic scaffolds
As may be evident from the above, to fabricate a multicomponent scaffold, different processing
parameters are required to guarantee optimal output (Table 3). To achieve this, a custom-built
double-headed MEW device was investigated. With this system, essential parameters such as
collector distance, processing temperature, feeding pressure and the acceleration voltage can
be adjusted separately for each nozzle.
Table 3. Set values for the fabrication of the multicomponent membrane.

Setting

Set value for MEW

Nozzle

22G

AP nozzle system

Voltage (kV)

6

12

Feeding pressure (bar)

2

0.1

Temperature (°C)

80

120

Collector distance (mm)

4

10

500

10

Collector speed (mm/min)

Set value for MES

A G-code pattern was designed which combined the box scaffold pattern and the circular
electrospun membrane. To ensure coordinate stacking of the two components the designed Gcode also did factor the distance between the two heads (65 mm).
Initial experiments investigated MES on top of the MEW scaffold. A box-shaped scaffold
consisting of 10 layers with the dimension of 7x7 mm was printed and after completion, the AP
nozzle system was moved to the middle of the left wall of the MEW scaffold starting clockwise
circular movements with an initial radius of 3.5 mm.
SEM images were taken from the sample to evaluate the surface morphology of the biphasic
scaffold (Figure 27 A and B). SEM images revealed the successful stacking of the electrospun
membrane on top of the melt electrowritten scaffold. However, it is noteworthy that sagging
of the electrospun component into the pores of the MEW scaffold can be observed.
Furthermore, compared to the surface investigated in chapter 4.1.4, it seems that the density
of the electrospun fibres is reduced. It is likely that this phenomenon is caused by the relatively
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high pore size, which complicates the attachment of the electrospun part directly on top of the
scaffold and leads to stretching of the fibres.
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Figure 27. SEM images of the biphasic scaffolds. (A and B) MES on top of the MEW scaffold. (C and D) MEW scaffold on top
of MES. Scalebars: A and C: 200 µm; B and D: 20 µm.

To address this issue, we further investigated the possibility to print a 5-layered MEW scaffold
consisting of the same dimensions as previously described on top of the electrospun
component. As illustrated in Figure 27 C and D, the surface of the electrospun membrane
demonstrates higher density compared to Figure 27 A and B. Furthermore, the thickness of the
electrospun component seems to be thicker when compared to the top-printed sample, even
though the quantitative thickness is hard to access from the images due to bending effects. The
MEW scaffold on top of the electrospun component demonstrates well-defined box-shaped
pores. Interestingly, no shielding effects from the electrospun upper part can be noticed.
Ultimately, these pilot experiments demonstrated the fabrication of a biphasic scaffold by
combining MES and MEW. As MES on top of the MEW scaffold resulted in a decrease of the
fibre density and additionally showed sagging effects, it can be assumed that this printing order
is unsuitable for the use as a barrier membrane against bacteria penetration. Conversely, MEW
on top of the membrane provided the integrity of both component of the biphasic scaffold.
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4.2.3 Summary
Experimental results highlight for the first time that a biphasic scaffold, comprising of melt
electrospun submicron fibres and box-shaped MEW scaffolds, can be easily assessed in a onestep process using a double headed printer configuration. It has been noticed that MES on top
of the MEW scaffold shows sagging effects which results in reduced fibre density. However, for
a successful use of this biphasic scaffold in clinical surgeries, the fabrication process must
guarantee the integrity of the single components. Even though MEW on top of the electrospun
component had no macroscopic effects on the integrity of the electrospun fibres, this process
order only enables MEW on one side of the electrospun component. Thus a 3-layered scaffold,
which offers GTR structures on both side of the electrospun core cannot be achieved. To
investigate a multiphasic scaffold, the deposition of the electrospun fibres on top of the MEW
scaffold needs to be improved. An interesting study would be to start MES on top of the MEW
scaffold at a higher collector speed and gradually slow down to the desired speed. This initial
fibre deposition could act as a support structure, by partially reducing the pore size and
facilitating fibre attachment on top of the scaffold.
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6. Conclusion
In this project, the combination of two powerful technologies (MES and MEW) in a one-step
process was investigated to fabricate a biphasic scaffold suitable for clinical application. MES
parameters were assessed to provide high quality fibres with small fibre diameters. Initial
experiments have demonstrated the ability to fabricate submicron fibres with a modified nozzle
system including an AP needle. To the best of our knowledge, these are the smallest fibres
produced via MES reported to date. However, there remains the need to evaluate the potential
of the membrane to prevent bacteria infiltration. Moreover, box-structured scaffolds with pore
sizes conductive to cell invasiveness were successfully prepared by MEW. By investigating a
custom-built double-headed MEW device we were able to successfully combine MES and MEW
to create a biphasic scaffold. These results indicate a promising base-material for further
modification and optimisation.
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7. Future perspective
At this stage the project is still in its infancy and needs to be followed up with more detailed
characterisation. As already mentioned in previous chapters, some fundamental studies of the
biphasic scaffold regarding its biocompatibility, mechanical strength and bacteria tightness
needs to be completed. Nevertheless, this primary work indicates great potential for further
development:

Incorporation of anti-bacterial properties
As may be evident from the preceding literature investigation, anti-bacterial properties of the
biphasic scaffold are an important factor which needs to be considered in further
investigations. An interesting approach would be the incorporation of anti-bacterial agents into
the melt electrowritten/ -spun fibres, which could be easily assessed by blending. However, it
is important to consider thermostability and sustained long-term release of the drug. As
recently explored by Eberle during her master thesis in the research group, MEW provides the
possibility for a coaxial printing-setup [77]. This opens the path to create core/shell fibre
structures, in which the active component could be incorporated into the core material. The
superior release behaviour from core/shell fibres has been demonstrated earlier by Zhang et
al. [78].

Combination of the biphasic scaffold with bioactive molecules and growth factors
The incorporation of bioactive molecules or growth factors into the MEW scaffold would be
another approach to improve the application of the biphasic scaffold. Studies of the last decade
revealed that coating of electrospun fibres with biomimetic calcium phosphate results in
increased bone formation [79, 80]. Thus, coating the melt electrowritten surface facing the
bone implant would be an interesting approach which needs to be considered in following
studies.
To improve the healing process of the device, coating of the scaffold facing the oral mucosa
with collagen could be advantageous. A recently developed electrochemical alignment
technique of collagen, referred to as electrochemical compaction, would be a simple method
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to provide highly robust bundles of collagen [81]. In general, this process is based on the
electrolysis of an aqueous monomeric collagen solution. Due to the amphoteric nature the
generated pH triggers repulsion from the same charged electrodes and leads to compaction at
the isoelectric point. This technique has been used in our previous work to incorporate drugloaded microspheres in a mechanical robust collagen matrix. However, an interesting
investigation would be the possibility to combine MEW scaffolds with the aligned collagen
structures (Figure 28).

Figure 28. Schematic representation of the electrocompaction process combined with a MEW scaffold.

This composition could lead to superior mechanical properties and as well to an increase wound
healing due to the excellent cell affinity of collagen. Furthermore, as already mentioned, there
also remains the possibility to incorporate drug-loaded microspheres into the hybrid scaffold
using electrochemical compaction. Especially this would be a suitable approach for
thermosensitive drugs, which cannot be processed using the prolonged elevated temperatures
required for MEW.
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Appendix A
(Start of part)
G91
G3 X0 Y0 I3.5 F10
G1 X0.05 Y0 F10
G3 X0 Y0 I3.45 F10
G1 X0.05 Y0 F10

.
.
.
G3 X0 Y0 I0.10 F10
G1 X0.05 Y0 F10
G3 X0 Y0 I0.05 F10
G1 X0.05 Y0 F10
G4 S60
(End of part)

Figure 29. G-code written to fabricate circular electrospun
membranes with a diameter of 7 mm.
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